aspirin has been researched along with Brain Hemorrhage in 171 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To establish the risks of ischemic stroke and intracranial bleeding among healthy older people receiving daily low-dose aspirin." | 9.69 | Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial. ( Cloud, GC; Donnan, GA; Eaton, CB; Fitzgerald, SM; Lockery, J; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Reid, CM; Shah, RC; Thao, LTP; Tran, C; Williamson, JD; Wolfe, R; Woods, RL, 2023) |
| "Ticagrelor is slightly better than clopidogrel and aspirin in preventing stroke, especially ischemic stroke, with significant safety risks." | 9.41 | Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis. ( Chen, Y; Li, D; Liu, S; Ma, X; Zhong, P, 2023) |
| "Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone." | 9.30 | Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. ( Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H, 2019) |
| "P2Y12 receptor inhibitor plus aspirin vs aspirin given within 24 h after acute noncardioembolic ischemic stroke or TIA reduces the risk of subsequent stroke." | 9.22 | P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis. ( Huang, WY; Lee, M; Ovbiagele, B, 2022) |
| "A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin." | 9.22 | Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016) |
| "In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention." | 9.22 | Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding." | 9.20 | Long-term use of ticagrelor in patients with prior myocardial infarction. ( Bansilal, S; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Fish, MP; Goto, S; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Magnani, G; Murphy, SA; Nicolau, JC; Oude Ophuis, T; Ruda, M; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Theroux, P; Wiviott, SD, 2015) |
| "Aspirin early after intravenous thrombolysis in acute ischemic stroke increases the risk of symptomatic intracranial hemorrhage (SICH), without influencing functional outcome at 3 months." | 9.19 | Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc analysis of the Antiplatelet Therapy in Combination with Recombinant t-PA Thrombolysis in Ischemic Stroke trial. ( Beenen, LF; de Haan, RJ; Majoie, CB; Marquering, HA; Roos, YB; Zinkstok, SM, 2014) |
| "In this multicentre, randomised, open-label trial with blind-endpoint assessment, patients with acute ischaemic stroke treated with alteplase were randomly assigned to 300 mg intravenous aspirin within 90 min after start of alteplase treatment or to no additional treatment." | 9.16 | Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. ( Roos, YB; Zinkstok, SM, 2012) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 9.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "In spite of the fact that the null hypothesis was not supported by our data, we found results supporting the safety (and potential efficacy) of ASA and tirofiban when used in the first hours of acute ischemic stroke." | 9.14 | Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. ( Boiti, C; Borutti, G; Cazzaniga, M; Falaschi, F; Maestroni, A; Mandelli, C; Manganaro, D; Monzani, V; Rossi, P; Torgano, G; Zecca, B; Zilioli, E, 2010) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 9.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "In the context of contemporary primary prevention guidelines, the effect of aspirin on myocardial infarction risk was significantly attenuated, whereas its major bleeding and hemorrhagic stroke complications were retained." | 9.01 | A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies. ( Khan, B; Khan, SA; Latham, SB; Rao, SV; Shah, R, 2019) |
| "Prior meta-analysis and observational studies have suggested that the bleeding risks associated with anticoagulation using vitamin K antagonists (VKA) or aspirin (ASA) are similar." | 8.93 | Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. ( Carrier, M; Gándara, E; Gonzalez, JP; LeGal, G; Vazquez, FJ, 2016) |
| " We found no evidence that the net benefit of aspirin increased with increasing risk of thrombosis, haemorrhage or poor functional outcome in all three trials." | 8.91 | Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials. ( Candelise, L; Chen, Z; Murray, GD; Sandercock, PA; Thompson, DD; Whiteley, WN, 2015) |
| "There is clinical equipoise between warfarin and aspirin for stroke prevention in patients with heart failure in sinus rhythm (SR)." | 8.89 | Warfarin versus aspirin for prevention of stroke in heart failure: a meta-analysis of randomized controlled clinical trials. ( Goyal, MK; Kumar, G, 2013) |
| "The risk-benefit profile of warfarin versus aspirin for patients with heart failure in normal sinus rhythm has not been definitively established." | 8.89 | Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Saver, JL; Wu, HC, 2013) |
| "To provide a pooled estimate of the bleeding risk from randomized controlled trials (RCTs) comparing warfarin and ASA at the dose ranges recommended in evidence-based guidelines." | 8.88 | Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis. ( Crowther, M; Donadini, MP; Lim, W; Spencer, FA; Warkentin, AE, 2012) |
| "Aspirin therapy reduces stroke by about 25% for persons with atherosclerotic vascular disease, but the effect in those without clinically apparent vascular disease is distinctly different." | 8.80 | Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. ( Benavente, O; Halperin, JL; Hart, RG; Kronmal, RA; Man-Son-Hing, M; McBride, R, 2000) |
| " Patients aged 80 years or older who received monotherapy with clopidogrel or aspirin following hospitalization for primary acute ischemic stroke between January 1, 2009, and December 31, 2018, were included." | 8.12 | Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke. ( Huang, HY; Katz, AJ; Lin, FJ; Lin, SY; Sheu, JJ; Wang, CC; Wu, CH, 2022) |
| " We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease." | 8.02 | Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. ( Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021) |
| "The effect of prestroke aspirin use on initial severity, hemorrhagic transformation, and functional outcome of ischemic stroke is uncertain." | 7.83 | Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, JC; Gorelick, PB; Han, MK; Hong, KS; Kang, K; Kim, DE; Kim, DH; Kim, JT; Ko, Y; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, JM; Park, TH; Yu, KH, 2016) |
| "Concomitant use of vitamin K antagonist (VKA) and aspirin (ASA) is becoming increasingly prevalent among atrial fibrillation (AF) patients." | 7.83 | Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry. ( Atarashi, H; Chishaki, A; Inoue, H; Kiyono, K; Kodama, I; Kodani, E; Lip, GY; Okumura, K; Okuyama, Y; Origasa, H; Watanabe, E; Yamamoto, M; Yamashita, T, 2016) |
| " We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy." | 7.81 | Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. ( Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY, 2015) |
| "Use of warfarin, low GCS score, opening to ventricle, older age, accompanying diabetes, and/or hypertension were worse prognostic factors." | 7.80 | Intracranial hemorrhages related with warfarin use and comparison of warfarin and acetylsalicylic acid. ( Beckmann, Y; Ciftçi, Y; Seçil, Y; Tokuçoğlu, F, 2014) |
| "As the management of patients treated with anticoagulants and antiplatelet drugs entails balancing coagulation levels, we evaluated the net clinical benefit of warfarin and aspirin on stroke in a large cohort of patients with atrial fibrillation (AF)." | 7.78 | A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. ( Azoulay, L; Dell'Aniello, S; Langleben, D; Renoux, C; Simon, TA; Suissa, S, 2012) |
| "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months." | 7.74 | Hemorrhage from a falx meningioma after internal use of low-dose aspirin. ( Miyazawa, T; Shima, K; Toyooka, T; Uozumi, Y, 2008) |
| "The Framingham Heart Study records of participants with atrial fibrillation (AF) during 1980 and 1994 were retrospectively reviewed to determine the prevalence of warfarin and aspirin use in AF." | 7.72 | Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). ( Benjamin, EJ; D'Agostino, RB; Lambert, JW; Levy, D; Massaro, JM; Sam, C; Wolf, PA, 2004) |
| "170 case-patients who developed intracranial hemorrhage during warfarin therapy and 1020 matched controls who did not; both case-patients and controls were taking warfarin for atrial fibrillation." | 7.72 | Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. ( Chang, Y; Fang, MC; Go, AS; Greenberg, SM; Hylek, EM; Rosand, J; Singer, DE, 2004) |
| "The recommended treatment of ischaemic stroke patients with atrial fibrillation (AF) is anticoagulation therapy with warfarin sodium and if this is contraindicated then aspirin should be used." | 7.70 | Which acute stroke patients with atrial fibrillation are prescribed warfarin therapy? Results from one-year's experience in Dundee. ( Craig, J; Goudie, BM; MacWalter, RS, 2000) |
| " As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies." | 6.58 | Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. ( Liu, X; Zhang, JJ, 2018) |
| "The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not been extensively studied." | 5.69 | Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion. ( Cai, T; Cao, M; Chen, X; Chen, Z; Cheng, D; Geng, W; Guo, C; He, P; He, W; Hu, J; Huang, F; Huang, J; Huang, W; Huang, X; Kong, W; Li, B; Li, F; Li, H; Li, L; Li, Z; Liang, H; Liu, C; Liu, J; Liu, S; Liu, W; Liu, Z; Luo, J; Miao, J; Mu, J; Nogueira, RG; Peng, Y; Qiu, Z; Saver, JL; Shi, Q; Shi, Z; Song, J; Tan, X; Tang, M; Tang, Y; Tian, Y; Wan, Y; Wang, D; Wang, M; Wang, P; Wu, Y; Xie, S; Xie, W; Yang, D; Yang, J; Yang, Q; Yang, S; Yao, L; Yu, Y; Yu, Z; Yue, C; Zhang, B; Zhao, H; Zheng, J; Zi, W, 2023) |
| "To establish the risks of ischemic stroke and intracranial bleeding among healthy older people receiving daily low-dose aspirin." | 5.69 | Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial. ( Cloud, GC; Donnan, GA; Eaton, CB; Fitzgerald, SM; Lockery, J; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Reid, CM; Shah, RC; Thao, LTP; Tran, C; Williamson, JD; Wolfe, R; Woods, RL, 2023) |
| "Our study suggested that tirofiban use appears to be safe as monotherapy in AIS treatment compared with common dual antiplatelet therapy, however, no improvement in functional outcomes was found." | 5.62 | Association between tirofiban monotherapy and efficacy and safety in acute ischemic stroke. ( Chen, C; Hu, W; Liu, D; Liu, J; Liu, T; Luo, W; Song, J; Tao, C; Yuan, X; Zhang, C; Zhu, Y, 2021) |
| "Ticagrelor is slightly better than clopidogrel and aspirin in preventing stroke, especially ischemic stroke, with significant safety risks." | 5.41 | Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis. ( Chen, Y; Li, D; Liu, S; Ma, X; Zhong, P, 2023) |
| "Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone." | 5.30 | Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. ( Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H, 2019) |
| "The objective was to assess whether rivaroxaban is superior to acetylsalicylic acid (ASA) in reducing the risk of clinically overt stroke, systemic embolism, or covert stroke among patients without apparent recurrent atrial arrhythmias for at least 1 year after their most recent AF ablation procedure." | 5.27 | The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. ( Birnie, DH; Champagne, J; Essebag, V; Gupta, D; Ha, ACT; Healey, JS; Heidbuchel, H; Hill, MD; Hindricks, G; Kirchhof, P; Sanders, P; Sharma, M; Verma, A; Wells, G; Wyse, DG, 2018) |
| " We identified patients with ICH from the overall trial population enrolled in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial who received ≥1 dose of the study drug (n = 18 140)." | 5.24 | Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. ( Al-Khatib, SM; Alexander, JH; Bushnell, CD; Diener, HC; Easton, JD; Gabriel Melo de Barros E Silva, P; Granger, CB; Guimarães, PO; Hanna, M; Held, C; Kolls, BJ; Lopes, RD; Thomas, L; Wallentin, L; Wojdyla, DM, 2017) |
| "P2Y12 receptor inhibitor plus aspirin vs aspirin given within 24 h after acute noncardioembolic ischemic stroke or TIA reduces the risk of subsequent stroke." | 5.22 | P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis. ( Huang, WY; Lee, M; Ovbiagele, B, 2022) |
| "A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin." | 5.22 | Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016) |
| "In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention." | 5.22 | Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding." | 5.20 | Long-term use of ticagrelor in patients with prior myocardial infarction. ( Bansilal, S; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Fish, MP; Goto, S; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Magnani, G; Murphy, SA; Nicolau, JC; Oude Ophuis, T; Ruda, M; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Theroux, P; Wiviott, SD, 2015) |
| "Aspirin early after intravenous thrombolysis in acute ischemic stroke increases the risk of symptomatic intracranial hemorrhage (SICH), without influencing functional outcome at 3 months." | 5.19 | Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc analysis of the Antiplatelet Therapy in Combination with Recombinant t-PA Thrombolysis in Ischemic Stroke trial. ( Beenen, LF; de Haan, RJ; Majoie, CB; Marquering, HA; Roos, YB; Zinkstok, SM, 2014) |
| "In this multicentre, randomised, open-label trial with blind-endpoint assessment, patients with acute ischaemic stroke treated with alteplase were randomly assigned to 300 mg intravenous aspirin within 90 min after start of alteplase treatment or to no additional treatment." | 5.16 | Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. ( Roos, YB; Zinkstok, SM, 2012) |
| "We present the protocol of a multicenter randomized clinical trial (n = 800) investigating the effects of immediate addition of aspirin to rt-PA on poor outcome (modified Rankin score >2) in ischemic stroke patients." | 5.14 | Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial. ( de Haan, RJ; Roos, YB; Stam, J; Vermeulen, M; Zinkstok, SM, 2010) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 5.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "In spite of the fact that the null hypothesis was not supported by our data, we found results supporting the safety (and potential efficacy) of ASA and tirofiban when used in the first hours of acute ischemic stroke." | 5.14 | Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. ( Boiti, C; Borutti, G; Cazzaniga, M; Falaschi, F; Maestroni, A; Mandelli, C; Manganaro, D; Monzani, V; Rossi, P; Torgano, G; Zecca, B; Zilioli, E, 2010) |
| " Randomized clinical trials that compared cilostazol to aspirin and reported the endpoints of ischemic stroke, intracranial hemorrhage and any bleeding were included." | 5.12 | Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis. ( Barrett, KM; Brott, TG; Ertekin-Taner, N; Gopal, N; Lin, MP; Meschia, JF; Ross, OA, 2021) |
| "Per 1200 persons taking aspirin for primary prevention for 5 years, there will be 4 fewer MACEs, 3 fewer ischaemic strokes, 3 more intracranial haemorrhages and 8 more major bleeding events." | 5.05 | A comparison of contemporary versus older studies of aspirin for primary prevention. ( Ebell, MH; Moriarty, F, 2020) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 5.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "In the context of contemporary primary prevention guidelines, the effect of aspirin on myocardial infarction risk was significantly attenuated, whereas its major bleeding and hemorrhagic stroke complications were retained." | 5.01 | A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies. ( Khan, B; Khan, SA; Latham, SB; Rao, SV; Shah, R, 2019) |
| "For stroke prevention in elderly patients with IS or TIA, DAPT is superior to aspirin monotherapy but appears to be equivalent to clopidogrel monotherapy, and is accompanied by an increased risk of bleeding." | 4.98 | Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis. ( Ding, L; Peng, B, 2018) |
| "Aspirin use in PVD might not be associated with improved cardiovascular outcomes or worse bleeding outcomes." | 4.95 | Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials. ( Bavry, AA; Elgendy, AY; Elgendy, IY; Mahmoud, AN; Mahtta, D; Rambarat, C, 2017) |
| "Prior meta-analysis and observational studies have suggested that the bleeding risks associated with anticoagulation using vitamin K antagonists (VKA) or aspirin (ASA) are similar." | 4.93 | Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. ( Carrier, M; Gándara, E; Gonzalez, JP; LeGal, G; Vazquez, FJ, 2016) |
| " We found no evidence that the net benefit of aspirin increased with increasing risk of thrombosis, haemorrhage or poor functional outcome in all three trials." | 4.91 | Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials. ( Candelise, L; Chen, Z; Murray, GD; Sandercock, PA; Thompson, DD; Whiteley, WN, 2015) |
| " Three preventive strategies were identified: (i) intra-operative transcranial Doppler (TCD) ultrasound and completion angioscopy which virtually abolished intra-operative stroke, primarily through the removal of residual luminal thrombus prior to restoration of flow; (ii) dual antiplatelet therapy with a single 75-mg dose of clopidogrel the night before surgery in addition to regular 75 mg aspirin which virtually abolished post-operative thromboembolic stroke and may also have contributed towards a decline in stroke/death following major cardiac events; and (iii) the provision of written guidance for managing post-CEA hypertension which was associated with virtual abolition of intracranial haemorrhage and stroke as a result of hyperperfusion syndrome." | 4.89 | Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy. ( Bell, PR; Bown, MJ; Dennis, MJ; London, NJ; McCarthy, MJ; Nasim, A; Naylor, AR; Sayers, RD, 2013) |
| "Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0." | 4.89 | Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2013) |
| "There is clinical equipoise between warfarin and aspirin for stroke prevention in patients with heart failure in sinus rhythm (SR)." | 4.89 | Warfarin versus aspirin for prevention of stroke in heart failure: a meta-analysis of randomized controlled clinical trials. ( Goyal, MK; Kumar, G, 2013) |
| "The risk-benefit profile of warfarin versus aspirin for patients with heart failure in normal sinus rhythm has not been definitively established." | 4.89 | Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Saver, JL; Wu, HC, 2013) |
| "To provide a pooled estimate of the bleeding risk from randomized controlled trials (RCTs) comparing warfarin and ASA at the dose ranges recommended in evidence-based guidelines." | 4.88 | Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis. ( Crowther, M; Donadini, MP; Lim, W; Spencer, FA; Warkentin, AE, 2012) |
| "Primary literature was identified through PubMed MEDLINE (1966-December 2007) and EMBASE (1980-December 2007) using the search terms anticoagulation, warfarin, aspirin, elderly, falls, older persons, atrial fibrillation, bleeding, education, stroke, and use." | 4.84 | Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. ( Corbett, TL; Garwood, CL, 2008) |
| "Aspirin therapy reduces stroke by about 25% for persons with atherosclerotic vascular disease, but the effect in those without clinically apparent vascular disease is distinctly different." | 4.80 | Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. ( Benavente, O; Halperin, JL; Hart, RG; Kronmal, RA; Man-Son-Hing, M; McBride, R, 2000) |
| " Patients aged 80 years or older who received monotherapy with clopidogrel or aspirin following hospitalization for primary acute ischemic stroke between January 1, 2009, and December 31, 2018, were included." | 4.12 | Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke. ( Huang, HY; Katz, AJ; Lin, FJ; Lin, SY; Sheu, JJ; Wang, CC; Wu, CH, 2022) |
| "To examine the association between CAC, bleeding, and ASCVD and explore the net estimated effect of aspirin at different CAC thresholds." | 4.02 | Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease. ( Ajufo, E; Ayers, CR; de Lemos, JA; Joshi, PH; Khera, A; Rohatgi, A; Vigen, R, 2021) |
| " We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease." | 4.02 | Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. ( Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021) |
| "We pooled individual patient data from 6 randomized clinical trials (CAPRIE [Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events], ESPS-2 [European Stroke Prevention Study-2], MATCH [Management of Atherothrombosis With Clopidogrel in High-Risk Patients], CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance], ESPRIT [European/Australasian Stroke Prevention in Reversible Ischemia Trial], and PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes]) investigating antiplatelet therapy in the subacute or chronic phase after noncardioembolic transient ischemic attack or stroke." | 4.02 | Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. ( Algra, A; Bath, PM; Csiba, L; Diener, HC; Greving, JP; Hacke, W; Hilkens, NA; Kappelle, LJ; Koudstaal, PJ; Leys, D; Mas, JL; Sacco, RL, 2021) |
| "Treatment of patients with stroke presenting with minor deficits remains controversial, and the recent Potential of rtPA for Ischemic Strokes with Mild Symptoms (PRISMS) trial, which randomized patients to thrombolysis vs aspirin, did not show benefit." | 3.91 | MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS. ( Benson, RT; Hsia, AW; Kalaria, CP; Latour, LL; Leigh, R; Luby, M; Lynch, JK; Majidi, S; Nadareishvili, Z, 2019) |
| "Of 149 subjects (mean age 57; 48% female; median NIH stroke scale (NIHSS) 19; 46% ischemic stroke; 54% hemorrhagic), implementation of treatments included: dysphagia screening (80%), deep venous thrombosis prophylaxis (0%), aspirin (83%), antihypertensives (89%) and statins (95%)." | 3.91 | Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania. ( Biseko, MR; Grundy, SJ; Kharal, GA; Klein, JP; Mateen, FJ; Mmbando, TN; Okeng'o, K; Parker, R; Regenhardt, RW; Saadi, A; Shayo, AF; Wibecan, L; Xu, A, 2019) |
| "We examined whether the efficacy of low-dose acetylsalicylic acid (aspirin) for primary prevention of cardiovascular events is influenced by blood pressure (BP) using data from patients aged 60-85 years with hypertension, dyslipidemia, and/or diabetes, but without cardiovascular disease of the Japanese Primary Prevention Project." | 3.91 | Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019) |
| "The effect of prestroke aspirin use on initial severity, hemorrhagic transformation, and functional outcome of ischemic stroke is uncertain." | 3.83 | Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, JC; Gorelick, PB; Han, MK; Hong, KS; Kang, K; Kim, DE; Kim, DH; Kim, JT; Ko, Y; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, JM; Park, TH; Yu, KH, 2016) |
| "Concomitant use of vitamin K antagonist (VKA) and aspirin (ASA) is becoming increasingly prevalent among atrial fibrillation (AF) patients." | 3.83 | Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry. ( Atarashi, H; Chishaki, A; Inoue, H; Kiyono, K; Kodama, I; Kodani, E; Lip, GY; Okumura, K; Okuyama, Y; Origasa, H; Watanabe, E; Yamamoto, M; Yamashita, T, 2016) |
| " We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy." | 3.81 | Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. ( Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY, 2015) |
| "We describe a case of a 67-year-old man who required emergency surgery for acute intracranial bleeding after having received a loading dose of aspirin and ticagrelor for an acute ST-elevation myocardial infarction." | 3.81 | Lack of Effect of Platelet Transfusions and Desmopressin on Intracranial Bleeding in a Patient Receiving Ticagrelor. ( Bonhomme, F; Cartier Faessler, V; Fontana, P; Maillard, J, 2015) |
| "Use of warfarin, low GCS score, opening to ventricle, older age, accompanying diabetes, and/or hypertension were worse prognostic factors." | 3.80 | Intracranial hemorrhages related with warfarin use and comparison of warfarin and acetylsalicylic acid. ( Beckmann, Y; Ciftçi, Y; Seçil, Y; Tokuçoğlu, F, 2014) |
| "To investigate the relationship between hemorrhagic stroke and use of antiplatelets and warfarin using data from The Health Improvement Network." | 3.79 | Antithrombotic drugs and risk of hemorrhagic stroke in the general population. ( Cookson, C; Gaist, D; García-Rodríguez, LA; González-Pérez, A; Morton, J, 2013) |
| "As the management of patients treated with anticoagulants and antiplatelet drugs entails balancing coagulation levels, we evaluated the net clinical benefit of warfarin and aspirin on stroke in a large cohort of patients with atrial fibrillation (AF)." | 3.78 | A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. ( Azoulay, L; Dell'Aniello, S; Langleben, D; Renoux, C; Simon, TA; Suissa, S, 2012) |
| "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months." | 3.74 | Hemorrhage from a falx meningioma after internal use of low-dose aspirin. ( Miyazawa, T; Shima, K; Toyooka, T; Uozumi, Y, 2008) |
| " We report a patient, having used aspirin for secondary stroke prevention, who had an acute cerebellar hemorrhage after taking nattokinase 400 mg daily for 7 consecutive days." | 3.74 | Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds. ( Chang, YY; Lai, SL; Lan, MY; Liu, JS; Wu, HS, 2008) |
| "The study assessed associations between visible infarction, time to randomisation, baseline neurological deficit, stroke syndrome, allocated aspirin or heparin treatment, recurrent haemorrhagic stroke, early death and six month functional outcome in the International Stroke Trial." | 3.72 | Visible infarction on computed tomography is an independent predictor of poor functional outcome after stroke, and not of haemorrhagic transformation. ( Lewis, SC; Mielke, O; Sandercock, PA; Wardlaw, JM; West, TM, 2003) |
| "In the recently published Warfarin Aspirin Recurrent Stroke Study (WARSS), a low-intensity anticoagulation regimen was used because of safety concerns." | 3.72 | Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. ( , 2003) |
| "Of 596 ischemic strokes, 32 percent occurred during warfarin therapy, 27 percent during aspirin therapy, and 42 percent during neither type of therapy." | 3.72 | Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. ( Chang, Y; Go, AS; Henault, LE; Hylek, EM; Jensvold, NG; Selby, JV; Singer, DE, 2003) |
| "The Framingham Heart Study records of participants with atrial fibrillation (AF) during 1980 and 1994 were retrospectively reviewed to determine the prevalence of warfarin and aspirin use in AF." | 3.72 | Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). ( Benjamin, EJ; D'Agostino, RB; Lambert, JW; Levy, D; Massaro, JM; Sam, C; Wolf, PA, 2004) |
| "170 case-patients who developed intracranial hemorrhage during warfarin therapy and 1020 matched controls who did not; both case-patients and controls were taking warfarin for atrial fibrillation." | 3.72 | Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. ( Chang, Y; Fang, MC; Go, AS; Greenberg, SM; Hylek, EM; Rosand, J; Singer, DE, 2004) |
| "Antenatal intake of low dose aspirin is advised for prevention of pregnancy induced hypertension, intrauterine growth retardation and pre-term labour." | 3.71 | Fetal intracranial hemorrhage due to antenatal low dose aspirin intake. ( Kutty, PM; Sajith, N; Sasidharan, CK, 2001) |
| "The recommended treatment of ischaemic stroke patients with atrial fibrillation (AF) is anticoagulation therapy with warfarin sodium and if this is contraindicated then aspirin should be used." | 3.70 | Which acute stroke patients with atrial fibrillation are prescribed warfarin therapy? Results from one-year's experience in Dundee. ( Craig, J; Goudie, BM; MacWalter, RS, 2000) |
| "Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with four parallel cohorts." | 2.82 | ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. ( Berkman, L; Cafferty, FH; Cameron, D; Coyle, C; Gilbert, D; Gupta, S; Kynaston, H; Langley, RE; MacKenzie, M; Pramesh, CS; Ring, A; Rowley, S; Wilson, RH, 2016) |
| "The rate of postoperative hemorrhage, average postoperative hemorrhage volume, and mortality rate were significantly higher in the ASA-sensitive patients who received ASA therapy compared with patients who did not receive ASA therapy (all p < 0." | 2.78 | Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage. ( Chen, J; Li, G; Li, X; Li, Y; Mao, J; Sun, Z; Xiang, Y; Yang, X; Ye, Y; Zhang, J; Zhang, M; Zhang, W; Zhao, J; Zhao, W, 2013) |
| "Major or severe bleeding (but not intracranial hemorrhage) was higher with orbofiban; it occurred in 2." | 2.69 | Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. ( Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG, 2000) |
| " As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies." | 2.58 | Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. ( Liu, X; Zhang, JJ, 2018) |
| "The hypothesis that intracranial hemorrhage risk would be higher with NOACs than aspirin was formulated during data collection." | 2.58 | Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis. ( Chiang, CE; Huang, WY; Lee, M; Ovbiagele, B; Singer, DE; Weng, HH; Wu, YL, 2018) |
| "Aspirin was associated with increased bleeding risks when combined with non-steroidal anti-inflammatory drugs, clopidogrel and selective serotonin reuptake inhibitors compared with monotherapy." | 2.53 | Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. ( García Rodríguez, LA; Hennekens, CH; Lanas, A; Martín-Pérez, M; Rothwell, PM, 2016) |
| "Key secondary endpoints include rate of intracranial hemorrhage progression, and intensive care unit- and hospital-free days." | 1.91 | The impact of low-dose aspirin in the Brain Injury Guidelines on outcomes in traumatic brain injury: A retrospective cohort study. ( Barton, CA; Gibson, E; Knapp, C; Munger, DN; Oetken, HJ; Plott, AJ; Schreiber, M; Webb, AJ, 2023) |
| "Spontaneous intracranial hemorrhage (ICH) is a frequent and severe consequence of primary brain tumors." | 1.91 | Antiplatelet medications and intracranial hemorrhage in patients with primary brain tumors. ( Elavalakanar, P; Ma, S; Marquez-Garcia, J; Miller, E; Neuberg, D; Panoff, S; Patell, R; Pinson, A; Ren, S; Sharma, R; Soman, S; Uhlmann, E; Weber, G; Zwicker, JI, 2023) |
| "Aspirin has traditionally been used as an analgesic and anti-inflammatory drug; however, low-dose aspirin is known to increase the risk of gastrointestinal and intracranial hemorrhage." | 1.62 | Big Data Analysis of the Risk of Intracranial Hemorrhage in Korean Populations Taking Low-Dose Aspirin. ( Kim, TG; Yu, S, 2021) |
| "Our study suggested that tirofiban use appears to be safe as monotherapy in AIS treatment compared with common dual antiplatelet therapy, however, no improvement in functional outcomes was found." | 1.62 | Association between tirofiban monotherapy and efficacy and safety in acute ischemic stroke. ( Chen, C; Hu, W; Liu, D; Liu, J; Liu, T; Luo, W; Song, J; Tao, C; Yuan, X; Zhang, C; Zhu, Y, 2021) |
| "Aspirin and warfarin were resumed at a median (IQR) of 5." | 1.56 | The Dilemma of Resuming Antithrombotic Therapy After Intracranial Hemorrhage in Patients With Left Ventricular Assist Devices. ( Asleh, R; Dawit, S; Freeman, WD; Li, Z; Matos, NL; O'Carroll, CB; Rabinstein, AA; Santos, CD, 2020) |
| "Among those developing intracranial hemorrhage, limited data are available to guide clinicians with antithrombotic reinitiation." | 1.56 | Warfarin Reinitiation After Intracranial Hemorrhage: A Case Series of Heart Valve Patients. ( Bungard, TJ; Butcher, K; Hodgson, M; Schultz, K; Wan, A, 2020) |
| "Post-LVAD strokes are an important cause of morbidity and reduced quality of life." | 1.48 | Cerebrovascular Accidents During Mechanical Circulatory Support: New Predictors of Ischemic and Hemorrhagic Strokes and Outcome. ( Ahmed, FS; Akbik, F; Feske, SK; Givertz, MM; Izzy, S; Renault, S; Rubin, DB; Smallwood, JA; Sylvester, KW; Vaitkevicius, H, 2018) |
| "The number of anticoagulated trauma patients is increasing." | 1.46 | Novel oral anticoagulants and trauma: The results of a prospective American Association for the Surgery of Trauma Multi-Institutional Trial. ( Barmparas, G; Bosarge, P; Brown, CV; Bukur, M; Carrick, MM; Catalano, RD; Coimbra, R; Holly-Nicolas, J; Inaba, K; Kaminski, S; Klein, AL; Kobayashi, L; Kopelman, T; Ley, EJ; Martinez, EM; Moore, FO; Murry, J; Nirula, R; Paul, D; Quick, J; Rivera, O; Schreiber, M, 2017) |
| "Flow diversion is increasingly used to treat intracranial aneurysms." | 1.43 | A New Protocol for Anticoagulation With Tirofiban During Flow Diversion. ( Chalouhi, N; Daou, B; Hasan, DM; Jabbour, P; Shields, B; Starke, RM, 2016) |
| "Only aspirin use was significantly associated with intracranial bleed (p=0." | 1.43 | The older they are the harder they fall: Injury patterns and outcomes by age after ground level falls. ( Bhattacharya, B; Davis, KA; Maung, A; Schuster, K, 2016) |
| "Aspirin (53." | 1.43 | Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. ( Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E, 2016) |
| "A total of 144 patients who had intracranial hemorrhage on initial CT scan (ASA group: 72; No-ASA group: 72) were enrolled." | 1.40 | Low-dose aspirin therapy is not a reason for repeating head computed tomographic scans in traumatic brain injury: a prospective study. ( Aziz, H; Friese, RS; Hashmi, A; Joseph, B; Kulvatunyou, N; O'Keeffe, T; Pandit, V; Rhee, P; Tang, A; Vercruysse, G; Wynne, J, 2014) |
| "Oral anticoagulation is the recommended treatment for stroke prevention in patients with atrial fibrillation." | 1.40 | Atrial fibrillation patients do not benefit from acetylsalicylic acid. ( Friberg, L; Själander, A; Själander, S; Svensson, PJ, 2014) |
| "All patients with intracranial hemorrhage on initial CT with prehospital CAP therapy were included." | 1.40 | Repeat head computed tomography in anticoagulated traumatic brain injury patients: still warranted. ( Aziz, H; Friese, RS; Joseph, B; Kulvatunyou, N; O'Keeffe, T; Pandit, V; Rhee, P; Sadoun, M; Tang, A; Wynne, JL, 2014) |
| "No new intracranial hemorrhages were observed in patients not receiving dual antiplatelet therapy." | 1.39 | Risk of hemorrhagic complication associated with ventriculoperitoneal shunt placement in aneurysmal subarachnoid hemorrhage patients on dual antiplatelet therapy. ( Bulsara, KR; Chalouhi, N; Hasan, DM; Howard, M; Jabbour, P; Kung, DK; Mahaney, KB; Smietana, J; Viljoen, S, 2013) |
| "Of the 500,000 brain injuries in the United States annually, 80% are considered mild (mild traumatic brain injury)." | 1.38 | Impact of age and anticoagulation: need for neurosurgical intervention in trauma patients with mild traumatic brain injury. ( Badellino, M; Moore, MM; Pasquale, MD, 2012) |
| "Previously, all reports of intracranial hemorrhages in MDMA abusers were associated with coingestion of other sympathomimetic drugs, or with pre-existing cerebrovascular lesions." | 1.38 | 3 cases of primary intracranial hemorrhage associated with "Molly", a purified form of 3,4-methylenedioxymethamphetamine (MDMA). ( Benveniste, RJ; Ferraro, N; Kahn, DE, 2012) |
| " Initial responders to transfusion received a greater volume of platelets, suggesting a dose-response relationship." | 1.37 | Assessment of platelet transfusion for reversal of aspirin after traumatic brain injury. ( Bachelani, AM; Bautz, JT; Billiar, TR; Corcos, A; Marshall, GT; Peitzman, AB; Sperry, JL; Zenati, M, 2011) |
| "A total of 3,436 trauma patients were identified, of whom 456 were taking anticoagulants (warfarin, n = 91 patients; aspirin, n = 228; clopidogrel, n = 43; and various combinations, n = 94)." | 1.37 | Impact of preinjury warfarin and antiplatelet agents on outcomes of trauma patients. ( Arnold-Lloyd, T; Ata, A; Bonville, DJ; Jahraus, CB; Rosati, C; Salem, L; Stain, SC, 2011) |
| "A newborn had a subdural hematoma detected with a prenatal ultrasonography at 31 weeks' gestation, probably in keeping with the regular treatment of AAS." | 1.30 | [Favorable outcome of a subdural hematoma diagnosed in utero]. ( Daussac, E; Lafont, M; Lamarque, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.58) | 18.2507 |
| 2000's | 39 (22.81) | 29.6817 |
| 2010's | 103 (60.23) | 24.3611 |
| 2020's | 28 (16.37) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, M | 2 |
| Yu, H | 1 |
| Li, Z | 3 |
| Gong, D | 1 |
| Liu, X | 2 |
| Huang, HY | 1 |
| Lin, SY | 1 |
| Katz, AJ | 1 |
| Sheu, JJ | 1 |
| Lin, FJ | 1 |
| Wang, CC | 1 |
| Wu, CH | 1 |
| Webb, AJ | 1 |
| Oetken, HJ | 1 |
| Plott, AJ | 1 |
| Knapp, C | 1 |
| Munger, DN | 1 |
| Gibson, E | 1 |
| Schreiber, M | 2 |
| Barton, CA | 1 |
| Ma, S | 1 |
| Patell, R | 1 |
| Miller, E | 1 |
| Ren, S | 1 |
| Marquez-Garcia, J | 1 |
| Panoff, S | 1 |
| Sharma, R | 2 |
| Pinson, A | 1 |
| Elavalakanar, P | 1 |
| Weber, G | 1 |
| Uhlmann, E | 1 |
| Neuberg, D | 1 |
| Soman, S | 1 |
| Zwicker, JI | 1 |
| Ma, X | 1 |
| Li, D | 1 |
| Liu, S | 2 |
| Chen, Y | 1 |
| Zhong, P | 1 |
| Klail, T | 1 |
| Sedova, P | 1 |
| Vinklarek, JF | 1 |
| Kovacova, I | 1 |
| Bar, M | 1 |
| Cihlar, F | 1 |
| Cernik, D | 1 |
| Kočí, L | 1 |
| Jura, R | 1 |
| Herzig, R | 1 |
| Husty, J | 1 |
| Kocher, M | 1 |
| Kovar, M | 1 |
| Nevšímalová, M | 1 |
| Raupach, J | 1 |
| Rocek, M | 1 |
| Sanak, D | 1 |
| Sevcik, P | 1 |
| Skoloudik, D | 1 |
| Sramek, M | 1 |
| Vanicek, J | 1 |
| Vaško, P | 1 |
| Vaclavik, D | 1 |
| Tomek, A | 1 |
| Mikulik, R | 1 |
| Zi, W | 1 |
| Song, J | 2 |
| Kong, W | 1 |
| Huang, J | 1 |
| Guo, C | 1 |
| He, W | 1 |
| Yu, Y | 1 |
| Zhang, B | 1 |
| Geng, W | 1 |
| Tan, X | 1 |
| Tian, Y | 2 |
| Liu, Z | 1 |
| Cao, M | 1 |
| Cheng, D | 1 |
| Li, B | 1 |
| Huang, W | 1 |
| Liu, J | 2 |
| Wang, P | 1 |
| Yu, Z | 1 |
| Liang, H | 1 |
| Yang, S | 1 |
| Tang, M | 1 |
| Liu, W | 2 |
| Huang, X | 1 |
| Tang, Y | 1 |
| Wu, Y | 1 |
| Yao, L | 1 |
| Shi, Z | 1 |
| He, P | 1 |
| Zhao, H | 1 |
| Chen, Z | 2 |
| Luo, J | 1 |
| Wan, Y | 1 |
| Shi, Q | 1 |
| Chen, X | 1 |
| Huang, F | 1 |
| Mu, J | 1 |
| Li, H | 1 |
| Zheng, J | 1 |
| Xie, S | 1 |
| Cai, T | 1 |
| Peng, Y | 2 |
| Xie, W | 1 |
| Qiu, Z | 1 |
| Liu, C | 2 |
| Yue, C | 1 |
| Li, L | 1 |
| Yang, D | 1 |
| Miao, J | 1 |
| Yang, J | 1 |
| Hu, J | 1 |
| Nogueira, RG | 1 |
| Wang, D | 1 |
| Saver, JL | 3 |
| Li, F | 1 |
| Yang, Q | 1 |
| Cloud, GC | 1 |
| Williamson, JD | 1 |
| Thao, LTP | 1 |
| Tran, C | 1 |
| Eaton, CB | 1 |
| Wolfe, R | 1 |
| Nelson, MR | 1 |
| Reid, CM | 1 |
| Newman, AB | 1 |
| Lockery, J | 1 |
| Fitzgerald, SM | 1 |
| Murray, AM | 1 |
| Shah, RC | 1 |
| Woods, RL | 1 |
| Donnan, GA | 1 |
| McNeil, JJ | 1 |
| Majidi, S | 1 |
| Luby, M | 1 |
| Lynch, JK | 1 |
| Hsia, AW | 1 |
| Benson, RT | 1 |
| Kalaria, CP | 1 |
| Nadareishvili, Z | 1 |
| Latour, LL | 1 |
| Leigh, R | 1 |
| Santos, CD | 1 |
| Matos, NL | 1 |
| Asleh, R | 1 |
| Dawit, S | 1 |
| Rabinstein, AA | 1 |
| O'Carroll, CB | 1 |
| Freeman, WD | 1 |
| Zheng, Y | 2 |
| Lieschke, F | 1 |
| Schaefer, JH | 1 |
| Wang, X | 1 |
| Foerch, C | 1 |
| van Leyen, K | 1 |
| Kim, SM | 1 |
| Jung, JM | 1 |
| Kim, BJ | 1 |
| Lee, JS | 2 |
| Kwon, SU | 1 |
| Moriarty, F | 1 |
| Ebell, MH | 1 |
| Wan, A | 1 |
| Butcher, K | 1 |
| Hodgson, M | 1 |
| Schultz, K | 1 |
| Bungard, TJ | 1 |
| Lan, L | 1 |
| Rong, X | 1 |
| Shen, Q | 1 |
| Gong, H | 1 |
| Li, X | 2 |
| Wang, H | 1 |
| Li, M | 1 |
| Pan, J | 1 |
| Zhang, X | 1 |
| Cucchiara, B | 1 |
| Elm, J | 1 |
| Easton, JD | 3 |
| Coutts, SB | 1 |
| Willey, JZ | 1 |
| Biros, MH | 1 |
| Ross, MA | 1 |
| Johnston, SC | 2 |
| Martí, D | 1 |
| Carballeira, D | 1 |
| Morales, MJ | 1 |
| Concepción, R | 1 |
| Del Castillo, H | 1 |
| Marschall, A | 1 |
| Delgado-Calva, FA | 1 |
| Dejuán-Bitriá, C | 1 |
| Pérez-Guzmán, J | 1 |
| López-Soberón, E | 1 |
| Palazuelos, J | 1 |
| Álvarez-Antón, S | 1 |
| Pande, SD | 1 |
| Win, MM | 1 |
| Khine, AA | 1 |
| Zaw, EM | 1 |
| Manoharraj, N | 1 |
| Lolong, L | 1 |
| Tin, AS | 1 |
| García Rodríguez, LA | 5 |
| Vora, P | 1 |
| Brobert, G | 1 |
| Soriano-Gabarró, M | 3 |
| Cea Soriano, L | 3 |
| Bouget, J | 1 |
| Balusson, F | 1 |
| Viglino, D | 1 |
| Roy, PM | 1 |
| Lacut, K | 1 |
| Pavageau, L | 1 |
| Oger, E | 1 |
| Conway, J | 1 |
| Friedman, BW | 1 |
| Ajufo, E | 1 |
| Ayers, CR | 1 |
| Vigen, R | 1 |
| Joshi, PH | 1 |
| Rohatgi, A | 1 |
| de Lemos, JA | 1 |
| Khera, A | 1 |
| Lin, MP | 1 |
| Meschia, JF | 1 |
| Gopal, N | 1 |
| Barrett, KM | 1 |
| Ross, OA | 1 |
| Ertekin-Taner, N | 1 |
| Brott, TG | 1 |
| Scavasine, VC | 1 |
| Barbosa, RM | 1 |
| Lopes Neto, FDN | 1 |
| Germininani, FMB | 1 |
| Bazan, R | 1 |
| Zétola, VF | 1 |
| Massaro, AR | 1 |
| Lange, MC | 1 |
| Ma, T | 1 |
| Jiang, T | 1 |
| Qin, H | 1 |
| Wu, R | 1 |
| Zhou, P | 1 |
| Ciolli, L | 1 |
| Lelli, N | 1 |
| Rosafio, F | 1 |
| Maffei, S | 1 |
| Sacchetti, F | 1 |
| Vandelli, L | 1 |
| Dell'Acqua, ML | 1 |
| Picchetto, L | 1 |
| Borzì, GM | 1 |
| Ricceri, R | 1 |
| Pentore, R | 1 |
| Tondelli, M | 1 |
| Vandelli, G | 1 |
| Rodríguez-Villatoro, N | 1 |
| Meletti, S | 1 |
| Zini, A | 1 |
| Vallone, S | 1 |
| Bigliardi, G | 1 |
| Kim, TG | 1 |
| Yu, S | 1 |
| Bálint, A | 1 |
| Tornyos, D | 1 |
| El Alaoui El Abdallaoui, O | 1 |
| Kupó, P | 1 |
| Komócsi, A | 1 |
| Tao, C | 1 |
| Zhu, Y | 2 |
| Zhang, C | 1 |
| Liu, T | 1 |
| Yuan, X | 1 |
| Luo, W | 1 |
| Chen, C | 1 |
| Liu, D | 1 |
| Hu, W | 1 |
| Hilkens, NA | 1 |
| Algra, A | 1 |
| Diener, HC | 2 |
| Bath, PM | 1 |
| Csiba, L | 1 |
| Hacke, W | 1 |
| Kappelle, LJ | 1 |
| Koudstaal, PJ | 1 |
| Leys, D | 1 |
| Mas, JL | 1 |
| Sacco, RL | 1 |
| Greving, JP | 1 |
| Huang, WY | 2 |
| Ovbiagele, B | 4 |
| Lee, M | 4 |
| Lopes, RD | 1 |
| Guimarães, PO | 1 |
| Kolls, BJ | 1 |
| Wojdyla, DM | 1 |
| Bushnell, CD | 1 |
| Hanna, M | 1 |
| Thomas, L | 1 |
| Wallentin, L | 1 |
| Al-Khatib, SM | 1 |
| Held, C | 1 |
| Gabriel Melo de Barros E Silva, P | 1 |
| Alexander, JH | 1 |
| Granger, CB | 1 |
| Gaist, D | 3 |
| Melkonian, M | 1 |
| Jarzebowski, W | 1 |
| Pautas, E | 1 |
| Siguret, V | 1 |
| Belmin, J | 1 |
| Lafuente-Lafuente, C | 1 |
| Mahmoud, AN | 1 |
| Elgendy, AY | 1 |
| Rambarat, C | 1 |
| Mahtta, D | 1 |
| Elgendy, IY | 1 |
| Bavry, AA | 1 |
| Kobayashi, L | 1 |
| Barmparas, G | 1 |
| Bosarge, P | 1 |
| Brown, CV | 1 |
| Bukur, M | 1 |
| Carrick, MM | 1 |
| Catalano, RD | 1 |
| Holly-Nicolas, J | 1 |
| Inaba, K | 1 |
| Kaminski, S | 2 |
| Klein, AL | 1 |
| Kopelman, T | 1 |
| Ley, EJ | 1 |
| Martinez, EM | 1 |
| Moore, FO | 1 |
| Murry, J | 1 |
| Nirula, R | 1 |
| Paul, D | 1 |
| Quick, J | 1 |
| Rivera, O | 1 |
| Coimbra, R | 1 |
| Jolobe, OMP | 1 |
| Verma, A | 1 |
| Ha, ACT | 1 |
| Kirchhof, P | 1 |
| Hindricks, G | 1 |
| Healey, JS | 1 |
| Hill, MD | 1 |
| Sharma, M | 1 |
| Wyse, DG | 1 |
| Champagne, J | 1 |
| Essebag, V | 1 |
| Wells, G | 1 |
| Gupta, D | 1 |
| Heidbuchel, H | 1 |
| Sanders, P | 1 |
| Birnie, DH | 1 |
| Zhang, JJ | 1 |
| Izzy, S | 1 |
| Rubin, DB | 1 |
| Ahmed, FS | 1 |
| Akbik, F | 1 |
| Renault, S | 1 |
| Sylvester, KW | 1 |
| Vaitkevicius, H | 1 |
| Smallwood, JA | 1 |
| Givertz, MM | 1 |
| Feske, SK | 1 |
| Evers, S | 1 |
| Ding, L | 1 |
| Peng, B | 1 |
| Cheng, KY | 1 |
| Tsang, CP | 1 |
| Leung, GKK | 1 |
| Lui, WM | 2 |
| Singer, DE | 4 |
| Wu, YL | 2 |
| Chiang, CE | 1 |
| Weng, HH | 1 |
| Tsivgoulis, G | 1 |
| Goyal, N | 1 |
| Kerro, A | 1 |
| Katsanos, AH | 1 |
| Krishnan, R | 1 |
| Malhotra, K | 1 |
| Pandhi, A | 1 |
| Duden, P | 1 |
| Deep, A | 1 |
| Shahripour, RB | 1 |
| Bryndziar, T | 1 |
| Nearing, K | 1 |
| Chulpayev, B | 1 |
| Chang, J | 1 |
| Zand, R | 1 |
| Alexandrov, AW | 1 |
| Alexandrov, AV | 2 |
| Gulati, S | 1 |
| Solheim, O | 1 |
| Carlsen, SM | 1 |
| Øie, LR | 1 |
| Jensberg, H | 1 |
| Gulati, AM | 1 |
| Madsbu, MA | 1 |
| Giannadakis, C | 1 |
| Jakola, AS | 1 |
| Salvesen, Ø | 1 |
| Regenhardt, RW | 1 |
| Biseko, MR | 1 |
| Shayo, AF | 1 |
| Mmbando, TN | 1 |
| Grundy, SJ | 1 |
| Xu, A | 1 |
| Saadi, A | 1 |
| Wibecan, L | 1 |
| Kharal, GA | 1 |
| Parker, R | 1 |
| Klein, JP | 1 |
| Mateen, FJ | 1 |
| Okeng'o, K | 1 |
| Fan, PY | 1 |
| Lee, CC | 1 |
| Liu, SH | 1 |
| Li, IJ | 1 |
| Weng, CH | 1 |
| Tu, KH | 1 |
| Hsieh, MY | 1 |
| Kuo, CF | 1 |
| Chang, TY | 1 |
| Tian, YC | 1 |
| Yang, CW | 1 |
| Wu, HH | 1 |
| Ando, K | 2 |
| Shimada, K | 2 |
| Yamazaki, T | 2 |
| Uchiyama, S | 2 |
| Uemura, Y | 1 |
| Ishizuka, N | 2 |
| Teramoto, T | 2 |
| Oikawa, S | 2 |
| Sugawara, M | 2 |
| Murata, M | 2 |
| Yokoyama, K | 2 |
| Ikeda, Y | 3 |
| Tillman, H | 1 |
| Farrant, M | 1 |
| Barsan, W | 1 |
| Elm, JJ | 1 |
| Kim, AS | 1 |
| Lindblad, AS | 1 |
| Palesch, YY | 1 |
| Shah, R | 1 |
| Khan, B | 1 |
| Latham, SB | 1 |
| Khan, SA | 1 |
| Rao, SV | 1 |
| Woo, PYM | 1 |
| Ng, BCF | 1 |
| Xiao, JX | 1 |
| Wong, D | 1 |
| Seto, A | 1 |
| Lam, S | 1 |
| Yim, C | 1 |
| Lo, HY | 1 |
| Po, YC | 1 |
| Wong, LYW | 1 |
| Lee, MWY | 1 |
| Yam, KY | 1 |
| Pu, JKS | 1 |
| Chan, KY | 1 |
| Poon, WS | 1 |
| Rosenberg, K | 1 |
| Narum, S | 1 |
| Solhaug, V | 1 |
| Myhr, K | 1 |
| Brørs, O | 1 |
| Kringen, MK | 1 |
| Seçil, Y | 1 |
| Ciftçi, Y | 1 |
| Tokuçoğlu, F | 1 |
| Beckmann, Y | 1 |
| Naylor, AR | 1 |
| Sayers, RD | 1 |
| McCarthy, MJ | 1 |
| Bown, MJ | 1 |
| Nasim, A | 1 |
| Dennis, MJ | 1 |
| London, NJ | 1 |
| Bell, PR | 1 |
| Mahaney, KB | 1 |
| Chalouhi, N | 2 |
| Viljoen, S | 1 |
| Smietana, J | 1 |
| Kung, DK | 1 |
| Jabbour, P | 2 |
| Bulsara, KR | 1 |
| Howard, M | 1 |
| Hasan, DM | 2 |
| Beynon, C | 1 |
| Scherer, M | 1 |
| Jakobs, M | 1 |
| Jung, C | 1 |
| Sakowitz, OW | 1 |
| Unterberg, AW | 1 |
| D'Amelio, M | 1 |
| Terruso, V | 1 |
| Famoso, G | 1 |
| Di Benedetto, N | 1 |
| Realmuto, S | 1 |
| Valentino, F | 1 |
| Ragonese, P | 1 |
| Savettieri, G | 1 |
| Aridon, P | 1 |
| García-Rodríguez, LA | 1 |
| Morton, J | 1 |
| Cookson, C | 1 |
| González-Pérez, A | 2 |
| Kansal, AR | 1 |
| Pokora, T | 1 |
| Sorensen, SV | 1 |
| Joseph, B | 3 |
| Aziz, H | 2 |
| Pandit, V | 3 |
| Kulvatunyou, N | 3 |
| O'Keeffe, T | 3 |
| Tang, A | 3 |
| Wynne, J | 1 |
| Hashmi, A | 1 |
| Vercruysse, G | 1 |
| Friese, RS | 3 |
| Rhee, P | 3 |
| Hong, KS | 3 |
| Rao, NM | 1 |
| Själander, S | 1 |
| Själander, A | 1 |
| Svensson, PJ | 1 |
| Friberg, L | 1 |
| Sadoun, M | 1 |
| Wynne, JL | 1 |
| Ciccone, A | 1 |
| Motto, C | 1 |
| Abraha, I | 1 |
| Cozzolino, F | 1 |
| Santilli, I | 1 |
| Jabbari, E | 1 |
| Sethuraman, S | 1 |
| Sekaran, L | 1 |
| Kayssi, A | 1 |
| Shaikh, F | 1 |
| Roche-Nagle, G | 1 |
| Brandao, LR | 1 |
| Williams, SA | 1 |
| Rubin, BB | 1 |
| Kirkman, MA | 1 |
| Citerio, G | 1 |
| Smith, M | 1 |
| Savonitto, S | 1 |
| Ferri, M | 1 |
| Corrada, E | 1 |
| Zinkstok, SM | 3 |
| Beenen, LF | 1 |
| Majoie, CB | 1 |
| Marquering, HA | 1 |
| de Haan, RJ | 2 |
| Roos, YB | 3 |
| Meyer, D | 1 |
| Butvidas, L | 1 |
| Khalil, M | 1 |
| Zangbar, B | 1 |
| Gries, L | 1 |
| Llull, L | 1 |
| Martín, V | 1 |
| Vidal, B | 1 |
| Cervera, A | 1 |
| Reddy, S | 1 |
| Grotts, J | 1 |
| Ferrigno, L | 1 |
| Eikelboom, JW | 1 |
| Hart, RG | 3 |
| Ho, CW | 1 |
| Ho, MH | 1 |
| Chan, PH | 2 |
| Hai, JJ | 2 |
| Cheung, E | 1 |
| Yeung, CY | 1 |
| Lau, KK | 2 |
| Chan, KH | 2 |
| Lau, CP | 2 |
| Lip, GY | 2 |
| Leung, GK | 2 |
| Tse, HF | 2 |
| Siu, CW | 3 |
| Jaben, EA | 1 |
| Mulay, SB | 1 |
| Stubbs, JR | 1 |
| Feng, X | 1 |
| Huan, Y | 1 |
| Lv, Y | 1 |
| Grandhi, R | 1 |
| Harrison, G | 1 |
| Voronovich, Z | 1 |
| Bauer, J | 1 |
| Chen, SH | 1 |
| Nicholas, D | 1 |
| Alarcon, LH | 1 |
| Okonkwo, DO | 1 |
| Bonaca, MP | 2 |
| Bhatt, DL | 2 |
| Cohen, M | 2 |
| Steg, PG | 2 |
| Storey, RF | 2 |
| Jensen, EC | 1 |
| Magnani, G | 1 |
| Bansilal, S | 1 |
| Fish, MP | 1 |
| Im, K | 1 |
| Bengtsson, O | 1 |
| Oude Ophuis, T | 1 |
| Budaj, A | 1 |
| Theroux, P | 1 |
| Ruda, M | 2 |
| Hamm, C | 1 |
| Goto, S | 2 |
| Spinar, J | 2 |
| Nicolau, JC | 1 |
| Kiss, RG | 1 |
| Murphy, SA | 1 |
| Wiviott, SD | 1 |
| Held, P | 2 |
| Braunwald, E | 3 |
| Sabatine, MS | 2 |
| Thompson, DD | 1 |
| Murray, GD | 1 |
| Candelise, L | 1 |
| Sandercock, PA | 2 |
| Whiteley, WN | 1 |
| Maillard, J | 1 |
| Cartier Faessler, V | 1 |
| Fontana, P | 1 |
| Bonhomme, F | 1 |
| Sáez, ME | 1 |
| Johansson, S | 1 |
| Himmelmann, A | 1 |
| Daou, B | 1 |
| Starke, RM | 1 |
| Shields, B | 1 |
| Ernstbrunner, L | 1 |
| Korn, G | 1 |
| Ernstbrunner, E | 1 |
| Auffarth, A | 1 |
| Tauber, M | 2 |
| Resch, H | 2 |
| Moroder, P | 2 |
| Pourafkari, L | 1 |
| Ghaffari, S | 1 |
| Khaki, N | 1 |
| Hobika, GH | 1 |
| Masnadi-Shirazi, K | 1 |
| Nader, ND | 1 |
| Wu, IC | 1 |
| Hsieh, HM | 1 |
| Yu, FJ | 1 |
| Wu, MC | 1 |
| Wu, TS | 1 |
| Wu, MT | 1 |
| Park, JM | 1 |
| Kang, K | 1 |
| Cho, YJ | 1 |
| Lee, KB | 1 |
| Park, TH | 1 |
| Lee, SJ | 1 |
| Ko, Y | 1 |
| Han, MK | 1 |
| Lee, J | 2 |
| Cha, JK | 1 |
| Kim, DH | 1 |
| Kim, DE | 1 |
| Kim, JT | 1 |
| Choi, JC | 1 |
| Yu, KH | 1 |
| Lee, BC | 1 |
| Gorelick, PB | 1 |
| Bae, HJ | 1 |
| Vazquez, FJ | 1 |
| Gonzalez, JP | 1 |
| LeGal, G | 1 |
| Carrier, M | 1 |
| Gándara, E | 1 |
| Wilson, N | 1 |
| Selak, V | 1 |
| Blakely, T | 1 |
| Leung, W | 1 |
| Clarke, P | 1 |
| Jackson, R | 1 |
| Knight, J | 1 |
| Nghiem, N | 1 |
| Watanabe, E | 1 |
| Yamamoto, M | 1 |
| Kodama, I | 1 |
| Inoue, H | 1 |
| Atarashi, H | 1 |
| Okumura, K | 1 |
| Yamashita, T | 1 |
| Kodani, E | 1 |
| Okuyama, Y | 1 |
| Chishaki, A | 1 |
| Kiyono, K | 1 |
| Origasa, H | 1 |
| Minematsu, K | 2 |
| Matsumoto, M | 1 |
| Bhattacharya, B | 1 |
| Maung, A | 1 |
| Schuster, K | 1 |
| Davis, KA | 1 |
| Martín-Pérez, M | 1 |
| Hennekens, CH | 1 |
| Rothwell, PM | 1 |
| Lanas, A | 1 |
| Fahed, E | 1 |
| Ghauche, J | 1 |
| Rahme, R | 1 |
| Okais, N | 1 |
| Samaha, E | 1 |
| Nohra, G | 1 |
| Rizk, T | 1 |
| Maarrawi, J | 1 |
| Menassa-Moussa, L | 1 |
| Moussa, R | 1 |
| Fletcher, RH | 1 |
| Goodrich, E | 1 |
| Mauri, L | 1 |
| Ophuis, TO | 1 |
| Seung, KB | 1 |
| Hu, D | 1 |
| Dalby, AJ | 1 |
| Jensen, E | 1 |
| Morrow, DA | 1 |
| Coyle, C | 1 |
| Cafferty, FH | 1 |
| Rowley, S | 1 |
| MacKenzie, M | 1 |
| Berkman, L | 1 |
| Gupta, S | 1 |
| Pramesh, CS | 1 |
| Gilbert, D | 1 |
| Kynaston, H | 1 |
| Cameron, D | 1 |
| Wilson, RH | 1 |
| Ring, A | 1 |
| Langley, RE | 1 |
| Wändell, P | 1 |
| Carlsson, AC | 1 |
| Holzmann, M | 1 |
| Ärnlöv, J | 1 |
| Johansson, SE | 1 |
| Sundquist, J | 1 |
| Sundquist, K | 1 |
| Ho, HH | 1 |
| Mok, KH | 1 |
| Cox, M | 1 |
| Bisangwa, S | 1 |
| Herpich, F | 1 |
| Crudele, A | 1 |
| Pineda, C | 1 |
| Stern, S | 1 |
| Cohen, MJ | 1 |
| Gilon, D | 1 |
| Leshno, M | 1 |
| Brezis, M | 1 |
| Marmagkiolis, K | 1 |
| Nikolaidis, IG | 1 |
| Politis, T | 1 |
| Goldstein, L | 1 |
| Cuisset, T | 2 |
| Frere, C | 2 |
| Quilici, J | 2 |
| Uhry, S | 1 |
| Alessi, MC | 2 |
| Bonnet, JL | 2 |
| Miyazawa, T | 1 |
| Uozumi, Y | 1 |
| Toyooka, T | 1 |
| Shima, K | 1 |
| Ivascu, FA | 1 |
| Howells, GA | 1 |
| Junn, FS | 1 |
| Bair, HA | 1 |
| Bendick, PJ | 1 |
| Janczyk, RJ | 1 |
| Georgiadis, D | 1 |
| Arnold, M | 1 |
| von Buedingen, HC | 1 |
| Valko, P | 1 |
| Sarikaya, H | 1 |
| Rousson, V | 1 |
| Mattle, HP | 1 |
| Bousser, MG | 1 |
| Baumgartner, RW | 2 |
| Boysen, G | 1 |
| Yu, SQ | 1 |
| Wang, JS | 1 |
| Ji, N | 1 |
| Qian, K | 1 |
| Cayla, G | 1 |
| Poyet, R | 1 |
| Gaborit, B | 1 |
| Bali, L | 1 |
| Morange, PE | 1 |
| Koller, H | 1 |
| Hitzl, W | 1 |
| Vermeulen, M | 1 |
| Stam, J | 1 |
| Guo, JJ | 1 |
| Xu, E | 1 |
| Lin, QY | 1 |
| Zeng, GL | 1 |
| Xie, HF | 1 |
| Major, J | 1 |
| Reed, MJ | 1 |
| Torgano, G | 1 |
| Zecca, B | 1 |
| Monzani, V | 1 |
| Maestroni, A | 1 |
| Rossi, P | 1 |
| Cazzaniga, M | 1 |
| Manganaro, D | 1 |
| Boiti, C | 1 |
| Zilioli, E | 1 |
| Borutti, G | 1 |
| Falaschi, F | 1 |
| Mandelli, C | 1 |
| Cordonnier, C | 1 |
| Hassan, AE | 1 |
| Zacharatos, H | 1 |
| Vazquez, G | 1 |
| Rodriguez, GJ | 1 |
| Suri, MF | 1 |
| Tummala, RP | 1 |
| Taylor, RA | 1 |
| Qureshi, AI | 1 |
| Mantha, S | 1 |
| Pianka, AM | 1 |
| Tsapatsaris, N | 1 |
| Chimowitz, MI | 1 |
| Lynn, MJ | 1 |
| Derdeyn, CP | 1 |
| Turan, TN | 1 |
| Fiorella, D | 1 |
| Lane, BF | 1 |
| Janis, LS | 1 |
| Lutsep, HL | 1 |
| Barnwell, SL | 1 |
| Waters, MF | 1 |
| Hoh, BL | 1 |
| Hourihane, JM | 1 |
| Levy, EI | 1 |
| Harrigan, MR | 1 |
| Chiu, D | 1 |
| Klucznik, RP | 1 |
| Clark, JM | 1 |
| McDougall, CG | 1 |
| Johnson, MD | 1 |
| Pride, GL | 1 |
| Torbey, MT | 1 |
| Zaidat, OO | 1 |
| Rumboldt, Z | 1 |
| Cloft, HJ | 1 |
| Bachelani, AM | 1 |
| Bautz, JT | 1 |
| Sperry, JL | 1 |
| Corcos, A | 1 |
| Zenati, M | 1 |
| Billiar, TR | 1 |
| Peitzman, AB | 1 |
| Marshall, GT | 1 |
| Bonville, DJ | 1 |
| Ata, A | 1 |
| Jahraus, CB | 1 |
| Arnold-Lloyd, T | 1 |
| Salem, L | 1 |
| Rosati, C | 1 |
| Stain, SC | 1 |
| Chong, BH | 1 |
| Pong, V | 1 |
| Chan, YH | 1 |
| Zuo, ML | 1 |
| Pu, JK | 1 |
| Warkentin, AE | 1 |
| Donadini, MP | 1 |
| Spencer, FA | 1 |
| Lim, W | 1 |
| Crowther, M | 1 |
| Krittalak, K | 1 |
| Sawanyawisuth, K | 1 |
| Tiamkao, S | 1 |
| Kim, CK | 1 |
| Kwon, HT | 1 |
| Kwon, HM | 1 |
| De Berardis, G | 1 |
| Lucisano, G | 1 |
| D'Ettorre, A | 1 |
| Pellegrini, F | 1 |
| Lepore, V | 1 |
| Tognoni, G | 1 |
| Nicolucci, A | 1 |
| Siller-Matula, JM | 1 |
| Moore, MM | 1 |
| Pasquale, MD | 1 |
| Badellino, M | 1 |
| Azoulay, L | 1 |
| Dell'Aniello, S | 1 |
| Simon, TA | 1 |
| Langleben, D | 1 |
| Renoux, C | 1 |
| Suissa, S | 1 |
| Parsons, MW | 1 |
| Levi, CR | 1 |
| DiNicolantonio, JJ | 1 |
| O'Keefe, JH | 1 |
| Lavie, CJ | 1 |
| Lund, JL | 1 |
| Stürmer, T | 1 |
| Toft-Sørensen, H | 1 |
| Kahn, DE | 1 |
| Ferraro, N | 1 |
| Benveniste, RJ | 1 |
| Sun, Z | 1 |
| Zhao, W | 1 |
| Zhang, J | 1 |
| Chen, J | 1 |
| Li, Y | 1 |
| Ye, Y | 1 |
| Zhao, J | 1 |
| Yang, X | 1 |
| Xiang, Y | 1 |
| Li, G | 1 |
| Mao, J | 1 |
| Zhang, W | 2 |
| Zhang, M | 1 |
| Kumar, G | 1 |
| Goyal, MK | 1 |
| Wu, HC | 1 |
| Gabis, LV | 1 |
| Yangala, R | 1 |
| Lenn, NJ | 1 |
| Wardlaw, JM | 1 |
| West, TM | 1 |
| Lewis, SC | 1 |
| Mielke, O | 1 |
| Schmülling, S | 1 |
| Rudolf, J | 1 |
| Strotmann-Tack, T | 1 |
| Grond, M | 1 |
| Schneweis, S | 1 |
| Sobesky, J | 1 |
| Thiel, A | 1 |
| Heiss, WD | 1 |
| Hylek, EM | 3 |
| Go, AS | 2 |
| Chang, Y | 2 |
| Jensvold, NG | 1 |
| Henault, LE | 1 |
| Selby, JV | 1 |
| Spektor, S | 1 |
| Agus, S | 1 |
| Merkin, V | 1 |
| Constantini, S | 1 |
| Sam, C | 1 |
| Massaro, JM | 1 |
| D'Agostino, RB | 1 |
| Levy, D | 1 |
| Lambert, JW | 1 |
| Wolf, PA | 1 |
| Benjamin, EJ | 1 |
| Fang, MC | 1 |
| Rosand, J | 1 |
| Greenberg, SM | 1 |
| Nitschmann, S | 1 |
| Hartung, HP | 1 |
| Siebler, M | 1 |
| Mihara, K | 1 |
| Aoki, T | 1 |
| Moriguchi, A | 1 |
| Maeda, M | 1 |
| Furuichi, Y | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Toyoda, K | 1 |
| Okada, Y | 1 |
| Ibayashi, S | 1 |
| Inoue, T | 1 |
| Yasumori, K | 1 |
| Fukui, D | 1 |
| Uwatoko, T | 1 |
| Makihara, N | 1 |
| Magnani, JW | 1 |
| Cattaneo, M | 1 |
| Deininger, MH | 1 |
| Adam, A | 1 |
| Van Velthoven, V | 1 |
| Chang, YY | 1 |
| Liu, JS | 1 |
| Lai, SL | 1 |
| Wu, HS | 1 |
| Lan, MY | 1 |
| Garwood, CL | 1 |
| Corbett, TL | 1 |
| Horn, W | 1 |
| Hoerauf, H | 1 |
| Lafont, M | 1 |
| Lamarque, M | 1 |
| Daussac, E | 1 |
| Halperin, JL | 1 |
| McBride, R | 1 |
| Benavente, O | 1 |
| Man-Son-Hing, M | 1 |
| Kronmal, RA | 1 |
| Cannon, CP | 1 |
| McCabe, CH | 1 |
| Wilcox, RG | 1 |
| Langer, A | 1 |
| Caspi, A | 1 |
| Berink, P | 1 |
| Lopez-Sendon, J | 1 |
| Toman, J | 1 |
| Charlesworth, A | 1 |
| Anders, RJ | 1 |
| Alexander, JC | 1 |
| Skene, A | 1 |
| Kawano, KI | 1 |
| Fujishima, K | 1 |
| Kondo, K | 1 |
| Umemura, K | 1 |
| Berwaerts, J | 1 |
| Webster, J | 1 |
| Jung, HH | 1 |
| Hess, K | 1 |
| Craig, J | 1 |
| MacWalter, RS | 2 |
| Goudie, BM | 1 |
| Dutta, D | 1 |
| Fraser, HW | 1 |
| Nimmo, MJ | 1 |
| Albers, GW | 1 |
| Dalen, JE | 1 |
| Laupacis, A | 1 |
| Manning, WJ | 1 |
| Petersen, P | 1 |
| Ross, AM | 1 |
| Molhoek, P | 1 |
| Lundergan, C | 1 |
| Knudtson, M | 1 |
| Draoui, Y | 1 |
| Regalado, L | 1 |
| Le Louer, V | 1 |
| Bigonzi, F | 1 |
| Schwartz, W | 1 |
| de Jong, E | 1 |
| Coyne, K | 1 |
| Sasidharan, CK | 1 |
| Kutty, PM | 1 |
| Sajith, N | 1 |
| Adhikari, M | 1 |
| Pillay, T | 1 |
| Nathoo, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| Major Bleeding Risk Associated With Antithrombotics : The SACHA (Surveillance Des Accidents Hémorragiques Graves Sous Antithrombotiques) Study[NCT02886533] | 6,484 participants (Actual) | Observational | 2013-01-01 | Completed | |||
| A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation[NCT00412984] | Phase 3 | 20,976 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Pharmacoepidemiological Study on the Risk of Bleeding in New Users of Low-dose Aspirin (ASA) in The Health Improvement Network (THIN), UK[NCT02550717] | 398,158 participants (Actual) | Observational | 2015-09-01 | Completed | |||
| Impact of Catheter Ablation of Atrial Tachyarrhythmias on ABC Stroke and ABC Bleeding Risk Scores[NCT05635864] | 150 participants (Anticipated) | Observational | 2021-06-03 | Recruiting | |||
| Risk of Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs: a Nationwide Study[NCT02481011] | 22,111 participants (Actual) | Observational | 2015-05-31 | Completed | |||
| Transient Electrocardiogram Assessment in Stroke Evaluation[NCT03301662] | 100 participants (Anticipated) | Observational | 2017-10-09 | Not yet recruiting | |||
| Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study[NCT03729401] | Phase 4 | 390 participants (Anticipated) | Interventional | 2019-08-22 | Suspended (stopped due to Testing supplies unavailable.) | ||
| A Randomized, Single Center Trial to Assess the Endothelial Function With Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of Acute Coronary Syndrome[NCT03881943] | Phase 4 | 200 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384] | Phase 3 | 50 participants (Actual) | Interventional | 2021-04-01 | Completed | ||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Japanese Primary Prevention Project With Aspirin in the Elderly With One or More Risk Factors of Vascular Events: JPPP[NCT00225849] | Phase 4 | 10,000 participants | Interventional | 2005-03-31 | Recruiting | ||
| Phase IV Study of Aspirin and Clopidogrel Therapy Tailored by Functional Thrombocyte Examination (PFA-100, LTA and VerifyNOW) in Acute Myocardial Infarction[NCT01381185] | Phase 4 | 154 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Intracranial Stenting in Non-acute Symptomatic Ischemic Stroke: an Open-label, Randomised Controlled Trial[NCT05063630] | 300 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | |||
| Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis:A Prospective Multi-center, Registry Trial[NCT01994161] | 840 participants (Anticipated) | Observational [Patient Registry] | 2012-12-31 | Recruiting | |||
| Wingspan One Year Vascular Imaging Events and Neurologic Outcomes (WOVEN)[NCT04221984] | 129 participants (Actual) | Observational [Patient Registry] | 2019-11-12 | Completed | |||
| Registry of Emergent Large veSsel oCclUsion duE to IntraCranial AtherosclerosiS[NCT05403593] | 600 participants (Anticipated) | Observational [Patient Registry] | 2021-12-15 | Recruiting | |||
| Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306] | Phase 3 | 3,020 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the Maurora® Sirolimus-Eluting Stent Versus the Apollo Stent in Intracranial Atherosclerotic Stenosis(Maurora ICAS Trial)[NCT05719883] | 156 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | |||
| Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis[NCT00576693] | Phase 3 | 451 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)[NCT00004732] | 2,502 participants (Actual) | Interventional | 2000-12-31 | Completed | |||
| Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)[NCT04948749] | 792 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | |||
| Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging[NCT05907629] | 300 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| The Effect of Early Administration of PCSK9 Inhibitor, Alirocumab to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile, a Single Center Study, Registry Based, Pragmatic, Prospective Trial[NCT06083961] | Phase 4 | 200 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | ||
| China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a New, Prospective, Multi-center, Randomized Controlled Trial in China[NCT01763320] | Phase 3 | 380 participants (Actual) | Interventional | 2014-03-05 | Completed | ||
| China Research for Severe Spontaneous Intracerebral Hemorrhage（CRISIH）[NCT05975398] | 450 participants (Anticipated) | Observational [Patient Registry] | 2022-07-01 | Recruiting | |||
| Effect and Safety of Surgical Intervention for Severe Spontaneous Intracerebral Hemorrhage Patients on Long-term Oral Antiplatelet Treatment[NCT05766865] | 450 participants (Actual) | Observational | 2019-07-10 | Completed | |||
| Low-Dose Tenecteplase in Covid-19 Patients With Acute Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT04558125] | Phase 4 | 2 participants (Actual) | Interventional | 2020-09-08 | Terminated (stopped due to Identification of eligible patients was slower than anticipated.) | ||
| Aspirin Discontinuation After Left Atrial Appendage Occlusion in Atrial Fibrillation[NCT03821883] | 1,120 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | |||
| English: Current Perspective of the Status of Anticoagulation in Clinical Practice in Primare Care. Spanish: Perspectiva Actual de la sitUación de la anticoaguLación en la práctica clínica de Atención Primaria.[NCT02273609] | 1,524 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| A Prospective Randomized Controlled Study of Additonal Left Atrial Appendage Electrical Isolation in Catheter Ablation Combined With Left Atrial Appendage Occlusion of Persistent Atrial Fibrillation[NCT04897204] | 120 participants (Anticipated) | Interventional | 2021-06-01 | Not yet recruiting | |||
| Rehabilitation of Patients With Atrial Fibrillation[NCT03035539] | 58 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 2356 |
| Warfarin | 3060 |
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 327 |
| Warfarin | 462 |
Death was defined as all-cause mortality. All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 603 |
| Warfarin | 669 |
Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death. CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 613 |
| Warfarin | 877 |
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 459 |
| Warfarin | 608 |
For descriptions of Stroke and SE, see Outcome Measure 1. For description of Major bleeding, see Outcome Measure 3. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 229 |
| Warfarin | 285 |
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.52 |
| Warfarin | 3.94 |
Rate=number of adjudicated major (ISTH) bleed events per 100 patient years. ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 2.13 |
| Warfarin | 3.09 |
Rate=Number of adjudicated stroke or SE events per 100 patient years. Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 1.27 |
| Warfarin | 1.60 |
"Rate=number of all bleeding events per 100 patient years. All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death." (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 18.08 |
| Warfarin | 25.82 |
(NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.21 |
| Warfarin | 4.06 |
Rate=number of major or CRNM bleed events per 100 patient years. Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death. CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | number of events / 100 patient years (Number) |
|---|---|
| Apixaban | 4.07 |
| Warfarin | 6.01 |
Rate=number of events of net-clinical benefit per 100 patient years. Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.01 |
| Warfarin | 4.09 |
AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD). SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD. Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD. Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued. Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| AE | SAE | Bleeding AE | Discontinuations due to AE | Deaths | |
| Apixaban | 7406 | 3182 | 2288 | 688 | 429 |
| Warfarin | 7521 | 3302 | 2961 | 758 | 468 |
All suspected efficacy events were adjudicated by the Central Events Committee (CEC). Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing. (NCT00412984)
Timeframe: "Time to first event in Intended Treatment Period: started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) | ||
|---|---|---|---|
| Ischemic or Unspecified Stroke | Hemorrhagic Stroke | Systemic Embolism | |
| Apixaban | 159 | 38 | 15 |
| Warfarin | 173 | 76 | 16 |
Rate=number of adjudicated GUSTO bleeding events per 100 patient years. GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention. GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) | |
|---|---|---|
| Severe (n=80, 172)) | Severe or Moderate (n=199, 328) | |
| Apixaban | 0.52 | 1.29 |
| Warfarin | 1.13 | 2.18 |
Rate=number of adjudicated TIMI bleeding events per 100 patient years. TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions. Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) | |
|---|---|---|
| Major (n=148, 256) | Major or Minor (n=239, 370) | |
| Apixaban | 0.96 | 1.55 |
| Warfarin | 1.69 | 2.46 |
Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) | |||
|---|---|---|---|---|
| Ischemic or Unspecified Stroke (n=162, 175) | Hemorrhagic Stroke (n=40, 78) | Systemic Embolism (n=15, 17) | Myocardial Infarction (n=90, 102) | |
| Apixaban | 0.97 | 0.24 | 0.09 | 0.53 |
| Warfarin | 1.05 | 0.47 | 0.10 | 0.61 |
Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. For description of ACD, see Outcome Measure 5. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Stroke / SE / Major Bleeding (n=521, 666) | Stroke / SE / All-Cause Death (ACD) (n=752, 837) | Stroke / SE / Major Bleeding / ACD (n=1009, 1168) | Stroke / SE / MI / ACD (n=810, 906) | Ischemic or Unspecified Stroke / ACD (n=725, 796) | Hemorrhagic Stroke / ACD (n=622, 703) | SE / ACD (n=613, 679) | MI / ACD (n=663, 740) | |
| Apixaban | 3.17 | 4.49 | 6.13 | 4.85 | 4.32 | 3.68 | 3.63 | 3.93 |
| Warfarin | 4.11 | 5.04 | 7.20 | 5.49 | 4.78 | 4.20 | 4.05 | 4.43 |
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
Any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days after enrollment OR any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days of any revascularization procedure of the qualifying symptomatic intracranial artery done during follow-up, OR an ischemic stroke in the territory of the symptomatic intracranial artery from day 31 after study entry to completion of follow-up. (NCT00576693)
Timeframe: Mean length of follow-up was 2.4 years
| Intervention | participants (Number) |
|---|---|
| Intensive Medical Management Plus Stenting | 52 |
| Intensive Medical Management Alone | 34 |
The primary aim of CREST is to assess if the efficacy of CAS differs from that of CEA in preventing stroke, myocardial infarction and death during a 30-day peri-procedural period, or ipsilateral stroke over the follow-up period in patients with symptomatic (>=50%) or asymptomatic (>=60%) extracranial carotid stenosis. Four-year follow-up, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. (NCT00004732)
Timeframe: 30 days and 4 years
| Intervention | Percentage (Mean) |
|---|---|
| Carotid-Artery Stenting | 7.2 |
| Carotid Endarterectomy | 6.8 |
4-year follow-up, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. (NCT00004732)
Timeframe: 4 years
| Intervention | Percentage (Mean) | |
|---|---|---|
| Men | Women | |
| Carotid Endarterectomy | 6.8 | 6.7 |
| Carotid-Artery Stenting | 6.2 | 8.9 |
32 reviews available for aspirin and Brain Hemorrhage
| Article | Year |
|---|---|
Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Gastrointestinal Hemorrhage; Humans; Intr | 2022 |
Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; Ische | 2023 |
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He | 2019 |
A comparison of contemporary versus older studies of aspirin for primary prevention.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Neo | 2020 |
Aspirin after Acute Ischemic Stroke.
Topics: Aspirin; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Stroke; Mortality; Odds Ratio; Plate | 2020 |
Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.
Topics: Aged; Anti-Inflammatory Agents; Aspirin; Cilostazol; Female; Humans; Intracranial Hemorrhages; Ische | 2021 |
P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis.
Topics: Aspirin; Cerebral Infarction; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhage | 2022 |
Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2017 |
Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials.
Topics: Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Myocardial Infarction; P | 2017 |
Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hema | 2018 |
Topics: Aspirin; Brain; General Practice; Humans; Intracranial Hemorrhages; United Kingdom | 2018 |
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; | 2018 |
Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Intracranial | 2018 |
A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Intracranial Hemorrhages; Platelet Aggregation | 2019 |
Caution Regarding Low-Dose Aspirin for Primary Prevention of Cardiovascular Events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Intracranial Hemor | 2019 |
Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy.
Topics: Angioscopy; Aspirin; Carotid Artery Diseases; Clinical Protocols; Clopidogrel; Drug Therapy, Combina | 2013 |
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benef | 2013 |
Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Human | 2013 |
Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Brain Ischemia; Humans; Immunoglobulin Fab Fragments; In | 2014 |
The intensive care management of acute ischemic stroke: an overview.
Topics: Airway Management; Anticoagulants; Aspirin; Decompressive Craniectomy; Endovascular Procedures; Fibr | 2014 |
Reversing the effects of antiplatelet agents in the setting of intracranial hemorrhage: a look at the literature.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Factor VIIa; Humans; Intracranial | 2015 |
Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials.
Topics: Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Intracranial Hemorr | 2015 |
Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Odds Rat | 2016 |
Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clopidogrel; Databases, F | 2016 |
Approach to and management of the acute stroke patient with atrial fibrillation: a literature review.
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Atrial Fibrillation; Factor VIIa; Heparin; Humans; | 2008 |
Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation; Confidence Intervals; Evidence- | 2012 |
Warfarin versus aspirin for prevention of stroke in heart failure: a meta-analysis of randomized controlled clinical trials.
Topics: Anticoagulants; Aspirin; Female; Heart Failure; Humans; Intracranial Hemorrhages; Male; Middle Aged; | 2013 |
Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis.
Topics: Anticoagulants; Aspirin; Chi-Square Distribution; Female; Fibrinolytic Agents; Heart Failure; Humans | 2013 |
Haemorrhagic stroke during anti-platelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Cerebral Hemorrhage; Clinical Trials as Topic; Humans; Intracrania | 2008 |
Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Int | 2008 |
Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; | 2000 |
Antithrombotic therapy in atrial fibrillation.
Topics: Administration, Oral; Aged; Aspirin; Atrial Fibrillation; Electric Countershock; Fibrinolytic Agents | 2001 |
23 trials available for aspirin and Brain Hemorrhage
| Article | Year |
|---|---|
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.
Topics: Aspirin; Brain Ischemia; Cerebral Arterial Diseases; Fibrinolytic Agents; Humans; Intracranial Hemor | 2023 |
Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Female; Humans; Intracranial Hemorrhages; Ischemic Stroke; Plate | 2023 |
Bleeding associated with low-dose aspirin: Comparison of data from the COMPASS randomized controlled trial and routine clinical practice.
Topics: Aspirin; Cohort Studies; Gastrointestinal Hemorrhage; Humans; Incidence; Intracranial Hemorrhages | 2020 |
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Female; | 2017 |
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, D | 2018 |
Dual antiplatelet therapy pretreatment in IV thrombolysis for acute ischemic stroke.
Topics: Administration, Intravenous; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; | 2018 |
Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Fema | 2018 |
Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2019 |
Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc analysis of the Antiplatelet Therapy in Combination with Recombinant t-PA Thrombolysis in Ischemic Stroke trial.
Topics: Aged; Aspirin; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pla | 2014 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Comorbidity; Diabetes Mellitus; Dyslipidemias; Fem | 2016 |
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
Topics: Adenosine; Aged; Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Intracranial Hemorrha | 2016 |
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Chemotherapy, Adjuvant; Colorect | 2016 |
Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Intracranial Hemorr | 2010 |
Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
Topics: Aspirin; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebr | 2009 |
Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Disability Evaluation; Do | 2010 |
Determinants of intracranial hemorrhage incidence in patients on oral anticoagulation followed at the Lahey clinic.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Blood Pressure; Case-Control Studies; Databases, Factual | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Early Ter | 2012 |
Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Aspirin; Basal Ganglia; Craniotomy; Doub | 2013 |
Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Administration | 2003 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Femal | 2000 |
Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Circulation; Enoxaparin; Female; Heparin; He | 2001 |
116 other studies available for aspirin and Brain Hemorrhage
| Article | Year |
|---|---|
Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke.
Topics: Aged; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrh | 2022 |
The impact of low-dose aspirin in the Brain Injury Guidelines on outcomes in traumatic brain injury: A retrospective cohort study.
Topics: Aspirin; Brain Injuries; Brain Injuries, Traumatic; Glasgow Coma Scale; Humans; Intracranial Hemorrh | 2023 |
Antiplatelet medications and intracranial hemorrhage in patients with primary brain tumors.
Topics: Aspirin; Brain Neoplasms; Humans; Intracranial Hemorrhages; Platelet Aggregation Inhibitors; Retrosp | 2023 |
Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Intracranial Hemorrhages; Ischemic Stroke; Mechanical | 2023 |
MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS.
Topics: Aged; Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Magnet | 2019 |
The Dilemma of Resuming Antithrombotic Therapy After Intracranial Hemorrhage in Patients With Left Ventricular Assist Devices.
Topics: Aged; Anticoagulants; Aspirin; Deprescriptions; Female; Fibrinolytic Agents; Heart Failure; Heart-As | 2020 |
Dual Antiplatelet Therapy Increases Hemorrhagic Transformation Following Thrombolytic Treatment in Experimental Stroke.
Topics: Animals; Aspirin; Clopidogrel; Coronary Thrombosis; Disease Models, Animal; Drug Therapy, Combinatio | 2019 |
Warfarin Reinitiation After Intracranial Hemorrhage: A Case Series of Heart Valve Patients.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Aortic Valve; Aspirin; Blood Coagulation Factors; Cer | 2020 |
Effect of alteplase versus aspirin plus clopidogrel in acute minor stroke.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Intracra | 2020 |
Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial.
Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Double-Blind Method; Female; Humans; Intracranial | 2020 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithro | 2020 |
Haemorrhagic transformation following ischaemic stroke: A retrospective study.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Hemorrhage; Humans; Intr | 2020 |
Major bleeding risk and mortality associated with antiplatelet drugs in real-world clinical practice. A prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Databases, Factual | 2020 |
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aspirin; Atherosclerosis; Cohort Studies; Coronary Artery Disease; Coronary Disease; Eye Hemo | 2021 |
Risk of Early Bleeding with Dual Antiplatelet Therapy in Acute Stroke and Transient Ischemic Attack Regardless of NIHSS Admission.
Topics: Aged; Aspirin; Brazil; Clopidogrel; Databases, Factual; Disability Evaluation; Drug Administration S | 2021 |
Comparative risk for intracranial hemorrhage related to new oral anticoagulants: A network meta-analysis.
Topics: Administration, Oral; Antithrombins; Aspirin; Clinical Trials, Phase III as Topic; Humans; Intracran | 2021 |
Platelet Function Monitoring Performed after Carotid Stenting during Endovascular Stroke Treatment Predicts Outcome.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Databases, Factual; Disability Evaluation; Drug Monito | 2021 |
Big Data Analysis of the Risk of Intracranial Hemorrhage in Korean Populations Taking Low-Dose Aspirin.
Topics: Adult; Aged; Aspirin; Big Data; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Protect | 2021 |
Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Cerebrovascular Disorders; Coronary Artery Disease; Humans; Intrac | 2021 |
Association between tirofiban monotherapy and efficacy and safety in acute ischemic stroke.
Topics: Aspirin; China; Clopidogrel; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Ischemic Stroke; | 2021 |
Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Intracranial Hemorrhages; Isc | 2021 |
Incidence of intracranial bleeds in new users of low-dose aspirin: a cohort study using The Health Improvement Network.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Follow-Up Studies; Hematoma, Subdur | 2017 |
Novel oral anticoagulants and trauma: The results of a prospective American Association for the Surgery of Trauma Multi-Institutional Trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dabigatran; Female; Humans; Injury | 2017 |
A comparison between vitamin K antagonists and new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as To | 2017 |
Cerebrovascular Accidents During Mechanical Circulatory Support: New Predictors of Ischemic and Hemorrhagic Strokes and Outcome.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Female; Heart Failure; Heart-Ass | 2018 |
The importance of validating intracranial bleeding diagnoses in The Health Improvement Network, United Kingdom: Misclassification of onset and its impact on the risk associated with low-dose aspirin therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Infarction; Cohort Studies; Diagnostic Errors; Dose-R | 2019 |
The application of point-of-care platelet function assay in guiding platelet transfusion in aspirin-users with intracranial haemorrhages.
Topics: Aspirin; Blood Platelets; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pilot Project | 2018 |
Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania.
Topics: Aged; Antihypertensive Agents; Aspirin; Brain Ischemia; Cohort Studies; Deglutition Disorders; Disab | 2019 |
Preventing arteriovenous shunt failure in hemodialysis patients: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriovenous Shunt, Surgical; Aspirin; Aspirin, Dip | 2019 |
Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Pressure; Diabetes Mellitus; Dyslipidemias; Female; Hemorrha | 2019 |
The importance of aspirin, catheterization accuracy, and catheter design in external ventricular drainage-related hemorrhage: a multicenter study of 1002 procedures.
Topics: Adult; Aged; Aspirin; Catheterization; Catheters; Drainage; Female; Humans; Intracranial Hemorrhages | 2019 |
Characterisation of non-warfarin-associated bleeding events reported to the Norwegian spontaneous reporting system.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Aging; Anti-Inflammatory Ag | 2013 |
Intracranial hemorrhages related with warfarin use and comparison of warfarin and acetylsalicylic acid.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation; | 2014 |
Risk of hemorrhagic complication associated with ventriculoperitoneal shunt placement in aneurysmal subarachnoid hemorrhage patients on dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Humans; Hydrocephalus; Intracranial An | 2013 |
Early dual therapy for Chinese adults with TIA.
Topics: Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Humans; Intracranial Hemorrhages; Is | 2013 |
Initial experiences with Multiplate® for rapid assessment of antiplatelet agent activity in neurosurgical emergencies.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Clopidogrel; Embolization | 2013 |
Early and late mortality of spontaneous hemorrhagic transformation of ischemic stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Cohort Studies; Disease Progressio | 2014 |
Antithrombotic drugs and risk of hemorrhagic stroke in the general population.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Cohort Studies; Female; Fibrinolytic | 2013 |
Low-dose aspirin therapy is not a reason for repeating head computed tomographic scans in traumatic brain injury: a prospective study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Injuries; Female; Head; Humans; Intracranial Hemorrhages; Ma | 2014 |
Atrial fibrillation patients do not benefit from acetylsalicylic acid.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Female; Gastr | 2014 |
Repeat head computed tomography in anticoagulated traumatic brain injury patients: still warranted.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Injuries; Clopidogrel; Cohort Studies | 2014 |
The clinical dilemma of treating transient ischaemic attack-like symptoms in patients with coexisting arteriovenous malformation.
Topics: Aged; Aspirin; Female; Humans; Intracranial Arteriovenous Malformations; Intracranial Hemorrhages; I | 2014 |
Management of acute limb ischemia in the pediatric population.
Topics: Acute Disease; Adolescent; Anticoagulants; Aspirin; Canada; Catheterization, Peripheral; Child; Chil | 2014 |
Fatal bleedings with prasugrel as part of triple antithrombotic therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Arteriovenous Malformations; Aspirin; Drug The | 2014 |
The significance of platelet count in traumatic brain injury patients on antiplatelet therapy.
Topics: Aged; Aspirin; Brain Injuries; Clopidogrel; Female; Humans; Intracranial Hemorrhages; Male; Platelet | 2014 |
Intracranial hemorrhage during dual antiplatelet therapy after percutaneous left atrial appendage closure.
Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans | 2014 |
Incidence of intracranial hemorrhage and outcomes after ground-level falls in geriatric trauma patients taking preinjury anticoagulants and antiplatelet agents.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Female; Humans; Int | 2014 |
Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Huma | 2015 |
Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2015 |
Letter by Feng et al regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracra | 2015 |
Response to letter regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracra | 2015 |
Preinjury warfarin, but not antiplatelet medications, increases mortality in elderly traumatic brain injury patients.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Brain Injuries; Clopidogrel; Female; Humans; In | 2015 |
Lack of Effect of Platelet Transfusions and Desmopressin on Intracranial Bleeding in a Patient Receiving Ticagrelor.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Deamino Arginine Vasopressin; Fatal Outcome; He | 2015 |
Incidence and Predictors of Hemorrhagic Stroke in Users of Low-Dose Acetylsalicylic Acid.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Fibrinolytic Agents; Humans; | 2015 |
A New Protocol for Anticoagulation With Tirofiban During Flow Diversion.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clinical Protocols; Clopidogrel; Embolizati | 2016 |
S100B serum protein cannot predict secondary intracranial haemorrhage after mild head injury in patients with low-dose acetylsalicylic acid prophylaxis.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Craniocerebral Trauma; Female; Humans; Intracranial He | 2016 |
Predictors of hospital mortality and serious complications in patients admitted with excessive warfarin anticoagulation.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hospital Mo | 2016 |
A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Databases, Factual; Female; Gastro | 2016 |
Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Humans; Intracranial Hemorrhages; Male; Mi | 2016 |
Decision-making in an era of cancer prevention via aspirin: New Zealand needs updated guidelines and risk calculators.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Decision-M | 2016 |
Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; | 2016 |
The older they are the harder they fall: Injury patterns and outcomes by age after ground level falls.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Comorbidity; Female; Follow-Up S | 2016 |
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebra | 2016 |
Review: Aspirin for CVD primary prevention increases gastrointestinal bleeding and hemorrhagic stroke.
Topics: Aspirin; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Platelet Aggregation Inhibit | 2016 |
Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation-a cohort study in primary care.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2017 |
Successful drug-coated balloon angioplasty and single anti-platelet therapy to treat an ischaemic stroke patient with haemorrhage and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Aspirin; Brain; Brain Ischemia; Coronary Angiography; | 2016 |
Fluid levels in the bleeding brain: a marker for coagulopathy and hematoma expansion.
Topics: Aged; Aphasia, Broca; Aspirin; Confusion; Dementia, Vascular; Humans; Intracranial Hemorrhages; Male | 2017 |
Cryptogenic stroke in a patient with a PFO: a decision analysis.
Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Decision Trees; Foramen Ovale, Patent; Humans; Int | 2008 |
Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder: shifting from antiplatelet resistance to bleeding risk assessment?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Fatal Outcome; Female; Humans; Intra | 2010 |
Hemorrhage from a falx meningioma after internal use of low-dose aspirin.
Topics: Aged; Aspirin; Cerebral Infarction; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; M | 2008 |
Predictors of mortality in trauma patients with intracranial hemorrhage on preinjury aspirin or clopidogrel.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulati | 2008 |
Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Female; Follow-Up Stu | 2009 |
ACTIVE A: balancing the benefits and risks of clopidogrel and aspirin.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Humans; Intracra | 2009 |
Risk analysis for aspirin and postoperative intracranial hemorrhage--report of 3 cases.
Topics: Aged; Anticoagulants; Aspirin; Fatal Outcome; Female; Humans; Intracranial Hemorrhages; Male; Postop | 2009 |
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Cell Ad | 2009 |
Secondary intracranial hemorrhage after mild head injury in patients with low-dose acetylsalicylate acid prophylaxis.
Topics: Aged; Aged, 80 and over; Aspirin; Craniocerebral Trauma; Female; Follow-Up Studies; Glasgow Coma Sca | 2009 |
A retrospective review of patients with head injury with coexistent anticoagulant and antiplatelet use admitted from a UK emergency department.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Craniocerebral Trauma; Em | 2009 |
Brain microbleeds.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Brain; Cerebral | 2010 |
Low risk of intracranial and systemic hemorrhages in patients on dual antiplatelet treatment beyond 1 month following neuroendovascular angioplasty and/or stent placement.
Topics: Angioplasty; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2012 |
The unmet need of patients with atrial fibrillation: AVERROES and the novel oral anticoagulants.
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp | 2011 |
Assessment of platelet transfusion for reversal of aspirin after traumatic brain injury.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Injuries; Cohort Studies; Female; Humans; Intracranial Hemor | 2011 |
Impact of preinjury warfarin and antiplatelet agents on outcomes of trauma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Child; Child, Preschool; Clopid | 2011 |
Use of aspirin in Chinese after recovery from primary intracranial haemorrhage.
Topics: Age Factors; Aspirin; Female; Follow-Up Studies; Humans; Intracranial Hemorrhages; Male; Middle Aged | 2012 |
Safety of withholding anticoagulation in patients with mechanical prosthetic valves and intracranial haemorrhage.
Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Modality Therapy; Comorbidity; Contrai | 2011 |
Safety of withholding anticoagulation in patients with mechanical prosthetic valves and intracranial haemorrhage.
Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Modality Therapy; Comorbidity; Contrai | 2011 |
Safety of withholding anticoagulation in patients with mechanical prosthetic valves and intracranial haemorrhage.
Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Modality Therapy; Comorbidity; Contrai | 2011 |
Safety of withholding anticoagulation in patients with mechanical prosthetic valves and intracranial haemorrhage.
Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Modality Therapy; Comorbidity; Contrai | 2011 |
No significant association of aspirin use with cerebral microbleeds in the asymptomatic elderly.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Humans; Intracranial Hemorrhages; Male; Platelet Aggregati | 2012 |
Association of aspirin use with major bleeding in patients with and without diabetes.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cohort Studi | 2012 |
Hemorrhagic complications associated with aspirin: an underestimated hazard in clinical practice?
Topics: Aspirin; Diabetes Mellitus; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; M | 2012 |
Impact of age and anticoagulation: need for neurosurgical intervention in trauma patients with mild traumatic brain injury.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Brain Injuries; Clopidogrel; Craniotomy; Decompressive C | 2012 |
A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Databases, F | 2012 |
Reperfusion trials for acute ischaemic stroke.
Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Male; Platelet Aggregation I | 2012 |
Tighter aspirin control urged for patients with diabetes. Taking aspirin increases bleeding risk that is not always outweighed by the potential benefits for patients with low cardiovascular disease risk.
Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dose-Response Relationship, Drug; Gas | 2010 |
Benefits and risks of aspirin use.
Topics: Aspirin; Diabetes Mellitus; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; M | 2012 |
Benefits and risks of aspirin use.
Topics: Aspirin; Diabetes Mellitus; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; M | 2012 |
3 cases of primary intracranial hemorrhage associated with "Molly", a purified form of 3,4-methylenedioxymethamphetamine (MDMA).
Topics: Adult; Alcohol Drinking; Amphetamine-Related Disorders; Anticoagulants; Aspirin; Cerebral Angiograph | 2012 |
Time lag to diagnosis of stroke in children.
Topics: Adolescent; Age Factors; Aspirin; Brain Ischemia; Child; Emergency Medical Services; Episode of Care | 2002 |
Visible infarction on computed tomography is an independent predictor of poor functional outcome after stroke, and not of haemorrhagic transformation.
Topics: Aged; Aspirin; Brain Infarction; Female; Fibrinolytic Agents; Follow-Up Studies; Heparin; Humans; In | 2003 |
Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.
Topics: Anticoagulants; Arterial Occlusive Diseases; Asia, Southeastern; Aspirin; Brain Ischemia; Dipyridamo | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Low-dose aspirin prophylaxis and risk of intracranial hemorrhage in patients older than 60 years of age with mild or moderate head injury: a prospective study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Injuries; Dose-Resp | 2003 |
Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study).
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Gastrointestin | 2004 |
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Case-Control Stu | 2004 |
[Cerebral secondary prevention--clopidogrel alone or in combination with ASS].
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Huma | 2005 |
Prohemorrhagic and bleeding time activities of recombinant tissue plasminogen activator, heparin, aspirin, and a glycoprotein IIb/IIIa antagonist.
Topics: Animals; Aspirin; Bleeding Time; Collagenases; Dose-Response Relationship, Drug; Fibrinolytic Agents | 2005 |
Antithrombotic therapy and predilection for cerebellar hemorrhage.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriosclerosis; Aspirin; Blo | 2007 |
Methodological considerations for interpretation of rates of major haemorrhage in studies of anticoagulant therapy for atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Bias; Humans; In | 2008 |
Free-hand bedside catheter evacuation of cerebellar hemorrhage.
Topics: Aged; Aspirin; Catheters, Indwelling; Cerebellar Diseases; Cerebellum; Cranial Fossa, Posterior; Dec | 2008 |
Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds.
Topics: Aspirin; Diffusion Magnetic Resonance Imaging; Female; Fibrinolytic Agents; Herb-Drug Interactions; | 2008 |
[Intravitreal injections during anticoagulant treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Aspirin; Bevacizumab; Cho | 2008 |
[Favorable outcome of a subdural hematoma diagnosed in utero].
Topics: Adult; Aspirin; Female; Fetal Growth Retardation; Follow-Up Studies; Hematoma, Subdural; Humans; Inf | 1999 |
ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery.
Topics: Amides; Animals; Arterial Occlusive Diseases; Aspirin; Bleeding Time; Cerebrovascular Circulation; F | 2000 |
Analysis of risk factors involved in oral-anticoagulant-related intracranial haemorrhages.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Case-Control Studi | 2000 |
Symptomatic secondary hemorrhagic transformation of ischemic Wallenberg's syndrome.
Topics: Adult; Aspirin; Humans; Intracranial Hemorrhages; Lateral Medullary Syndrome; Magnetic Resonance Ima | 2000 |
Which acute stroke patients with atrial fibrillation are prescribed warfarin therapy? Results from one-year's experience in Dundee.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Contraindications; Female; Hospitalization; H | 2000 |
The importance of identifying intracranial haemorrhage as a cause of transient focal neurological symptoms.
Topics: Adult; Aspirin; Diagnosis, Differential; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, | 2000 |
Fetal intracranial hemorrhage due to antenatal low dose aspirin intake.
Topics: Abnormalities, Drug-Induced; Adult; Aspirin; Cesarean Section; Dose-Response Relationship, Drug; Fem | 2001 |
Aspirin and trauma--uncommon and preventable causes of intracranial haemorrhage in the newborn.
Topics: Adult; Aspirin; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Int | 2002 |